Document:

THIS WARRANT, AND THE SECURITIES ISSUABLE UPON THE EXERCISE
OF THIS WARRANT, HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ ACT”), OR ANY STATE SECURITIES
LAWS. THEY MAY NOT BE SOLD, OFFERED FOR SALE, PLEDGED, OR HYPOTHECATED IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT RELATED
THERETO OR AN OPINION OF COUNSEL (WHICH MAY BE COMPANY COUNSEL) REASONABLY SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS
NOT REQUIRED UNDER THE ACT, OR ANY APPLICABLE STATE SECURITIES LAWS.

 

WARRANT AGREEMENT

 

To Purchase Shares of Common Stock of

 

NEURALSTEM, INC.

 

Dated as of March 22, 2013 (the “Effective
Date”)

 

WHEREAS, the Neuralstem, Inc., a Delaware corporation desires
to grant [*], (the “Warrantholder”), in consideration for, among other things, financial advisory services,
the right to purchase shares of Common Stock (as defined below) pursuant to this Warrant Agreement (the “Agreement”);

 

NOW, THEREFORE, in consideration for providing financial advisory
services, and in consideration of the mutual covenants and agreements contained herein, the Company and Warrantholder agree as
follows:

 

SECTION 1.          GRANT
OF THE RIGHT TO PURCHASE COMMON STOCK.

 

For value received, the Company hereby grants to the Warrantholder,
and the Warrantholder is entitled, upon the terms and subject to the conditions hereinafter set forth, to subscribe for and purchase,
from the Company, an aggregate number of fully paid and non-assessable shares of the Common Stock equal to the quotient derived
by dividing (a) $[*] by (b) the Exercise Price (defined below). As used herein, the following terms shall have the following meanings:

 

“Act” means the Securities Act
of 1933, as amended.

 

“Company” means Neuralstem, Inc.,
a Delaware corporation, and any successor or surviving entity that assumes the obligations of the Company under this Agreement
pursuant to Section 8(a).

 

“Charter” means the Company’s
Articles of Incorporation, Certificate of Incorporation or other constitutional document, as may be amended from time to time.

 

“Common Stock” means the Company’s
common stock, $0.01 par value per share;

 

“Exercise Price” means $1.07892,
subject to adjustment pursuant to Section 8.

 

“Merger Event” means any sale,
lease or other transfer of all or substantially all assets of the Company or any merger or consolidation involving the Company
in which the Company is not the surviving entity, or in which the outstanding shares of the Company’s capital stock are otherwise
converted into or exchanged for shares of Common stock, other securities or property of another entity;

 

“Purchase Price” means, with respect
to any exercise of this Agreement, an amount equal to the Exercise Price as of the relevant time multiplied by the number of shares
of Common Stock requested to be exercised under this Agreement pursuant to such exercise; and

 

“SEC” means Securities and Exchange
Commission.

 

    	1

    	 

    

 

SECTION 2.       TERM
OF THE AGREEMENT.

 

Except as otherwise provided for herein, the term of this Agreement
and the right to purchase Common Stock as granted herein (the “Warrant) shall commence on the Effective Date and shall be
exercisable for a period ending five (5) years from the Effective Date.

 

SECTION 3.       EXERCISE
OF THE PURCHASE RIGHTS.

 

(a)          Exercise.
The purchase rights set forth in this Agreement are exercisable by the Warrantholder, in whole or in part, at any time, or from
time to time, prior to the expiration of the term set forth in Section 2, by tendering to the Company at its principal office a
notice of exercise in the form attached hereto as Exhibit I (the “Notice of Exercise”), duly completed
and executed. Promptly upon receipt of the Notice of Exercise and the payment of the Purchase Price in accordance with the terms
set forth below, and in no event later than three (3) days thereafter, the Company shall issue to the Warrantholder a certificate
for the number of shares of Common Stock purchased and shall execute the acknowledgment of exercise in the form attached hereto
as Exhibit II (the “Acknowledgment of Exercise”) indicating the number of shares which remain subject
to future purchases, if any.

 

The Purchase Price may be paid at the Warrantholder’s
election either (i) by cash or check, or (ii) in the event that there is not an effective registration statement covering the shares
underlying this Warrant, by surrender of all or a portion of the Warrant for shares of Common Stock to be exercised under this
Agreement and, if applicable, an amended Agreement representing the remaining number of shares purchasable hereunder, as determined
below (“Net Issuance”). Notwithstanding the foregoing, a Net Issuance will not be allowed prior to September
22, 2013. If the Warrantholder elects the Net Issuance method, the Company will issue Common Stock in accordance with the following
formula:

 

X = Y(A-B)

A

 

	Where:	X =	the number of shares of Common Stock to be issued to the Warrantholder.
	 	 	 
	 	Y =	the number of shares of Common Stock requested to be exercised under this Agreement.
	 	 	 
	 	A =	the fair market value of one (1) share of Common Stock at the time of issuance of such shares of Common Stock.
	 	 	 
	 	B =	the Exercise Price.

 

For purposes of the above calculation, current fair market value
of Common Stock shall mean with respect to each share of Common Stock:

 

(i)          if
the Common Stock is traded on a securities exchange, the fair market value shall be deemed to be the product of (x) the average
of the closing prices over a five (5) day period ending three days before the day the current fair market value of the securities
is being determined and (y) the number of shares of Common Stock into which each share of Common Stock is convertible at the time
of such exercise; or

 

(ii)         if
the Common Stock is traded over-the-counter, the fair market value shall be deemed to be the product of (x) the average of the
closing bid and asked prices quoted on the NASDAQ system (or similar system) over the five (5) day period ending three days before
the day the current fair market value of the securities is being determined and (y) the number of shares of Common Stock into which
each share of Common Stock is convertible at the time of such exercise;

 

(iii)        if
at any time the Common Stock is not listed on any securities exchange or quoted in the NASDAQ National Market or the over-the-counter
market, the current fair market value of Common Stock shall be the highest price per share which the Company could obtain from
a willing buyer (not a current employee or director) for shares of Common Stock sold by the Company, from authorized but unissued
shares, as determined in good faith by its Board of Directors, unless the Company shall become subject to a Merger Event, in which
case the fair market value of Common Stock shall be deemed to be the per share value received by the holders of the Company’s
Common Stock on a common equivalent basis pursuant to such Merger Event.

 

    	2

    	 

    

 

Upon partial exercise by either cash or Net Issuance, the Company
shall promptly issue an amended Agreement representing the remaining number of shares purchasable hereunder. All other terms and
conditions of such amended Agreement shall be identical to those contained herein, including, but not limited to the Effective
Date hereof.

 

(b)           Exercise
Prior to Expiration. To the extent this Agreement is not previously exercised as to all Common Stock subject hereto, and if
the fair market value of one share of the Common Stock is greater than the Exercise Price then in effect, and the Warrant may be
exercised on a Net Issuance basis, then this Agreement shall be deemed automatically exercised pursuant to Section 3(a) (even if
not surrendered) immediately before its expiration. For purposes of such automatic exercise, the fair market value of one share
of the Common Stock upon such expiration shall be determined pursuant to Section 3(a). To the extent this Agreement or any portion
thereof is deemed automatically exercised pursuant to this Section 3(b), the Company agrees to promptly notify the Warrantholder
of the number of shares of Common Stock, if any, the Warrantholder is to receive by reason of such automatic exercise. For purposes
of clarity, if the shares underlying the Warrant are subject to an effective registration statement, automatic exercise pursuant
to this Section 3(b) will not be permitted.

 

SECTION 4.          RESERVATION
OF SHARES.

 

During the term of this Agreement, the Company will at all times
have authorized and reserved a sufficient number of shares of its Common Stock to provide for the exercise of the rights to purchase
Common Stock as provided for herein.

 

SECTION 5.          NO
FRACTIONAL SHARES OR SCRIP.

 

No fractional shares or scrip representing fractional shares
shall be issued upon the exercise of this Agreement, but in lieu of such fractional shares the Company shall make a cash payment
therefor upon the basis of the Exercise Price then in effect.

 

SECTION 6.          NO
RIGHTS AS STOCKHOLDER.

 

This Agreement does not entitle the Warrantholder to any voting
rights or other rights as a stockholder of the Company prior to the exercise of this Agreement.

 

SECTION 7.          WARRANTHOLDER
REGISTRY.

 

The Company shall maintain a registry showing the name and address
of the registered holder of this Agreement. Warrantholder’s initial address, for purposes of such registry, is set forth
below Warrantholder’s signature on this Agreement. Warrantholder may change such address by giving written notice of such
changed address to the Company.

 

SECTION 8.          ADJUSTMENT
RIGHTS.

 

The Exercise Price and the number of shares of Common Stock
purchasable hereunder are subject to adjustment, as follows:

 

    	3

    	 

    

 

(a)          Merger
Event. If at any time there shall be Merger Event, then, as a part of such Merger Event, lawful provision shall be made so
that the Warrantholder shall thereafter be entitled to receive, upon exercise of this Agreement, the number of shares of Common
stock or other securities or property (collectively, “Reference Property”) that the Warrantholder would have
received in connection with such Merger Event if Warrantholder had exercised this Agreement immediately prior to the Merger Event.
In any such case, appropriate adjustment (as determined in good faith by the Company’s Board of Directors and reasonably
acceptable to the Warrantholder) shall be made in the application of the provisions of this Agreement with respect to the rights
and interests of the Warrantholder after the Merger Event to the end that the provisions of this Agreement (including adjustments
of the Exercise Price and adjustments to ensure that the provisions of this Section 8 shall thereafter be applicable, as nearly
as possible, to the purchase rights under this Agreement in relation to any Reference Property thereafter acquirable upon exercise
of such purchase rights) shall continue to be applicable in their entirety, and to the greatest extent possible. Without limiting
the foregoing, in connection with any Merger Event, upon the closing thereof, the successor or surviving entity shall assume the
obligations of this Agreement; provided that if the Reference Property includes shares of stock or other securities and assets
of an entity other than the successor or purchasing company, as the case may be, in such Merger Event, then such other entity shall
assume the obligations under this Agreement and any such assumption shall contain such additional provisions to protect the interests
of the Warrantholder as reasonably necessary by reason of the foregoing (as determined in good faith by the Company’s Board
of Directors and reasonably acceptable to the Warrantholder). In connection with a Merger Event and upon Warrantholder’s
written election to the Company, the Company shall cause this Warrant Agreement to be exchanged for the consideration that Warrantholder
would have received if Warrantholder had chosen to exercise its right to have shares issued pursuant to the Net Issuance provisions
of this Warrant Agreement without actually exercising such right, acquiring such shares and exchanging such shares for such consideration.
The provisions of this Section 8(a) shall similarly apply to successive Merger Events.

 

(b)          Reclassification
of Shares. Except for Merger Events subject to Section 8(a), and subject to Section 8(f), if the Company at any time shall,
by combination, reclassification, exchange or subdivision of securities or otherwise, change any of the securities as to which
purchase rights under this Agreement exist into the same or a different number of securities of any other class or classes, this
Agreement shall thereafter represent the right to acquire such number and kind of securities as would have been issuable as the
result of such change with respect to the securities which were subject to the purchase rights under this Agreement immediately
prior to such combination, reclassification, exchange, subdivision or other change. The provisions of this Section 8(b) shall similarly
apply to successive combination, reclassification, exchange, subdivision or other change.

 

(c)          Subdivision
or Combination of Shares. If the Company at any time shall combine or subdivide its Common Stock, (i) in the case of a subdivision,
the Exercise Price shall be proportionately decreased, or (ii) in the case of a combination, the Exercise Price shall be proportionately
increased.

 

(d)          Stock
Dividends. If the Company at any time while this Agreement is outstanding and unexpired shall:

 

(i)          pay
a dividend with respect to the Common Stock payable in Common Stock, then the Exercise Price shall be adjusted, from and after
the date of determination of stockholders entitled to receive such dividend or distribution, to that price determined by multiplying
the Exercise Price in effect immediately prior to such date of determination by a fraction (A) the numerator of which shall be
the total number of shares of Common Stock outstanding immediately prior to such dividend or distribution, and (B) the denominator
of which shall be the total number of shares of Common Stock outstanding immediately after such dividend or distribution; or

 

(ii)         make
any other distribution with respect to Common Stock, except any distribution specifically provided for in any other clause of this
Section 8, then, in each such case, provision shall be made by the Company such that the Warrantholder shall receive upon
exercise or conversion of this Warrant a proportionate share of any such distribution as though it were the holder of the Common
Stock as of the record date fixed for the determination of the stockholders of the Company entitled to receive such distribution.

 

(e)          Antidilution
Rights. Additional antidilution rights applicable to the Common Stock purchasable hereunder are as set forth in the Charter
and shall be applicable with respect to the Common Stock issuable hereunder. The Company shall promptly provide the Warrantholder
with any restatement, amendment, modification or waiver of the Charter; provided, that no such amendment, modification or
waiver shall impair or reduce the antidilution rights applicable to the Common Stock as of the date hereof unless such amendment,
modification or waiver affects the rights of Warrantholder with respect to the Common Stock in the same manner as it affects all
other holders of Common Stock. The Company shall provide Warrantholder with prior written notice of any issuance of its stock or
other equity security to occur after the Effective Date of this Agreement, which notice shall include (a) the price at which such
stock or security is to be sold, (b) the number of shares to be issued, and (c) such other information as necessary for Warrantholder
to determine if a dilutive event has occurred. For the avoidance of doubt, there shall be no duplicate anti-dilution adjustment
pursuant to this subsection (e), the foregoing subsection (d) and the Charter.

 

    	4

    	 

    

 

(f)          Notice
of Adjustments. If: (i) the Company shall declare any dividend or distribution upon its stock, whether in stock, cash, property
or other securities (assuming Warrantholder consents to a dividend involving cash, property or other securities); (ii) the Company
shall offer for subscription prorata to the holders of its Common Stock or other capital stock any additional shares of stock of
any class or other rights; (iii) there shall be any Merger Event; (iv) the Company shall sell, lease, license or otherwise transfer
all or substantially all of its assets; or (v) there shall be any voluntary dissolution, liquidation or winding up of the Company;
then, in connection with each such event, the Company shall send to the Warrantholder: (A) at least thirty (30) days’ prior
written notice of the date on which the books of the Company shall close or a record shall be taken for such dividend, distribution,
subscription rights (specifying the date on which the holders of Common Stock shall be entitled thereto) or for determining rights
to vote in respect of such Merger Event, dissolution, liquidation or winding up; and (B) in the case of any such Merger Event,
sale, lease, license or other transfer of all or substantially all assets, dissolution, liquidation or winding up, at least thirty
(30) days’ prior written notice of the date when the same shall take place (and specifying the date on which the holders
of Common Stock shall be entitled to exchange their Common Stock for securities or other property deliverable upon such Merger
Event, dissolution, liquidation or winding up).

 

Each such written notice shall set forth, in reasonable detail,
(i) the event requiring the notice, and (ii) if any adjustment is required to be made, (A) the amount of such adjustment, (B) the
method by which such adjustment was calculated, (C) the adjusted Exercise Price (if the Exercise Price has been adjusted), and
(D) the number of shares subject to purchase hereunder after giving effect to such adjustment, and shall be given by first class
mail, postage prepaid, or by reputable overnight courier with all charges prepaid, addressed to the Warrantholder at the address
for Warrantholder set forth in the registry referred to in Section 7.

 

(g)          Timely
Notice. Failure to timely provide such notice required by subsection (f) above shall entitle Warrantholder to retain the benefit
of the applicable notice period notwithstanding anything to the contrary contained in any insufficient notice received by Warrantholder.
For purposes of this subsection (g), and notwithstanding anything to the contrary in Section 12(g), the notice period shall begin
on the date Warrantholder actually receives a written notice containing all the information required to be provided in such subsection
(f). Notwithstanding the foregoing, notice shall be deemed given in the event that the Company discloses such information via a
filing on the SEC’s Edgar website and delivers to Warrantholder an electronic link to such filing information.

 

SECTION 9.       REPRESENTATIONS,
WARRANTIES AND COVENANTS OF THE COMPANY.

 

(a)          Reservation
of Common Stock. The Common Stock issuable upon exercise of the Warrantholder’s rights has been duly and validly reserved
and, when issued in accordance with the provisions of this Agreement, will be validly issued, fully paid and non-assessable, and
will be free of any taxes, liens, charges or encumbrances of any nature whatsoever; provided, that the Common Stock issuable
pursuant to this Agreement may be subject to restrictions on transfer under state and/or federal securities laws. The Company has
made available to the Warrantholder true, correct and complete copies of its Charter and current bylaws. The issuance of certificates
for shares of Common Stock upon exercise of this Agreement shall be made without charge to the Warrantholder for any issuance tax
in respect thereof, or other cost incurred by the Company in connection with such exercise and the related issuance of shares of
Common Stock; provided, that the Company shall not be required to pay any tax which may be payable in respect of any transfer
and the issuance and delivery of any certificate in a name other than that of the Warrantholder.

 

    	5

    	 

    

 

(b)          Due
Authority. The execution and delivery by the Company of this Agreement and the performance of all obligations of the Company
hereunder, including the issuance to Warrantholder of the right to acquire the shares of Common Stock and the Common Stock into
which it may be converted, have been duly authorized by all necessary corporate action on the part of the Company. This Agreement:
(1) does not violate the Company’s Charter or current bylaws; (2) does not contravene any law or governmental rule, regulation
or order applicable to it; and (3) does not and will not contravene any provision of, or constitute a default under, any indenture,
mortgage, contract or other instrument to which it is a party or by which it is bound. This Agreement constitutes a legal, valid
and binding agreement of the Company, enforceable in accordance with its terms.

 

(c)          Consents
and Approvals. No consent or approval of, giving of notice to, registration with, or taking of any other action in respect
of any state, federal or other governmental authority or agency is required with respect to the execution, delivery and performance
by the Company of its obligations under this Agreement, except for the filing of notices pursuant to Regulation D under the Act
and any filing required by applicable state securities law, which filings will be effective by the time required thereby.

 

(d)          Issued
Securities. All issued and outstanding shares of Common Stock, Common Stock or any other securities of the Company have been
duly authorized and validly issued and are fully paid and nonassessable. All outstanding shares of Common Stock, Common Stock and
any other securities were issued in full compliance with all federal and state securities laws. In addition,
as of the date immediately preceding the date of this Agreement:

 

(i)          The
authorized capital of the Company consists of (A) 150,000,000 shares of Common Stock, of which 68,447,314 shares are issued and
outstanding, and (B) 7,000,000 shares of Preferred Stock, of which 0 shares are issued and outstanding and are convertible into
n/a shares of Common Stock at $n/a per share.

 

(ii)         The
Company has reserved 38,564,368 shares of Common Stock for issuance under its Stock Option Plan(s), under which 16,787,287 options
are outstanding. Additionally, the Company has reserved 20,211,667 shares of Common Stock for issuance pursuant to outstanding
warrants, restricted stock units and other convertible securities. There are no other options, warrants, conversion privileges
or other rights presently outstanding to purchase or otherwise acquire any authorized but unissued shares of the Company’s
capital stock or other securities of the Company. The Company has no outstanding loans to any employee, officer or director of
the Company, and the Company agrees not to enter into any such loan or otherwise guarantee the payment of any loan made to an employee,
officer or director by a third party.

 

(iii)        In
accordance with the Company’s Charter, no stockholder of the Company has preemptive rights to purchase new issuances of the
Company’s capital stock.

 

(e)          [Intentionally
omitted.]

 

(f)          [Intentionally
omitted.]

 

(g)         Exempt
Transaction. Subject to the accuracy of the Warrantholder’s representations in Section 10, the issuance of this Warrant
and the Common Stock upon exercise of this Agreement will each constitute a transaction exempt from (i) the registration requirements
of Section 5 of the Act, in reliance upon Section 4(2) thereof, and (ii) the qualification requirements of the applicable state
securities laws.

 

    	6

    	 

    

 

(h)          Compliance
with Rule 144. If the Warrantholder proposes to sell Common Stock issuable upon the exercise of this Agreement in compliance
with Rule 144 promulgated by the SEC, then, upon Warrantholder’s written request to the Company, the Company shall furnish
to the Warrantholder, within ten days after receipt of such request, a written statement confirming the Company’s compliance
with the filing requirements of the SEC as set forth in such Rule, as such Rule may be amended from time to time. The Company will
use commercially reasonable efforts to maintain compliance with Rule 144 periodic reporting requirements.

 

(i)          [Intentionally
omitted.]

 

SECTION 10.    REPRESENTATIONS
AND COVENANTS OF THE WARRANTHOLDER.

 

This Agreement has been entered into by the Company in reliance
upon the following representations and covenants of the Warrantholder:

 

(a)          Investment
Purpose. This Warrant and the right to acquire the Common Stock are being acquired for investment and not with a view to the
sale or distribution of any part thereof, and the Warrantholder has no present intention of selling or engaging in any public distribution
of such rights or the Common Stock except pursuant to an effective registration statement or an exemption from the registration
requirements of the Act.

 

(b)          Private
Issue. The Warrantholder understands (i) that the Warrant and the Common Stock issuable upon exercise of this Agreement are
not registered under the Act or qualified under applicable state securities laws on the ground that the issuance contemplated by
this Agreement will be exempt from the registration and qualifications requirements thereof, and (ii) that the Company’s
reliance on such exemption is predicated on the representations set forth in this Section 10.

 

(c)          Financial
Risk. The Warrantholder has such knowledge and experience in financial and business matters as to be capable of evaluating
the merits and risks of its investment, and has the ability to bear the economic risks of its investment.

 

(d)          Risk
of No Registration. The Warrantholder understands that if the Company does not register with the SEC pursuant to Section 12
of the Securities Exchange Act of 1934 (the “1934 Act”), or file reports pursuant to Section 15(d) of the 1934
Act, or if a registration statement covering the securities under the Act is not in effect when it desires to sell (i) the rights
to purchase Common Stock pursuant to this Agreement or (ii) the Common Stock issuable upon exercise of the right to purchase, it
may be required to hold such securities for an indefinite period. The Warrantholder also understands that any sale of (A) its
rights hereunder to purchase Common Stock or (B) Common Stock issued or issuable hereunder which might be made by it in reliance
upon Rule 144 under the Act may be made only in accordance with the terms and conditions of that Rule.

 

(e)          Accredited
Investor. Warrantholder is an “accredited investor” within the meaning of the Securities and Exchange Rule 501
of Regulation D, as presently in effect.

 

SECTION 11.    TRANSFERS.

 

Subject to compliance with applicable federal and state securities
laws, this Agreement and all rights hereunder are transferable, in whole or in part, without charge to the holder hereof (except
for transfer taxes) upon surrender of this Agreement properly endorsed. Each taker and holder of this Agreement, by taking or holding
the same, consents and agrees that this Agreement, when endorsed in blank, shall be deemed negotiable, and that the holder hereof,
when this Agreement shall have been so endorsed and its transfer recorded on the Company’s books, shall be treated by the
Company and all other persons dealing with this Agreement as the absolute owner hereof for any purpose and as the person entitled
to exercise the rights represented by this Agreement. The transfer of this Agreement shall be recorded on the books of the Company
upon receipt by the Company of a notice of transfer in the form attached hereto as Exhibit III (the “Transfer Notice”),
at its principal offices and the payment to the Company of all transfer taxes and other governmental charges imposed on such transfer.
Until the Company receives such Transfer Notice, the Company may treat the registered owner hereof as the owner for all purposes.

 

    	7

    	 

    

 

SECTION 12.    MISCELLANEOUS.

 

(a)          Effective
Date. The provisions of this Agreement shall be construed and shall be given effect in all respects as if it had been executed
and delivered by the Company on the date hereof. This Agreement shall be binding upon any successors or assigns of the Company.

 

(b)          Remedies.
In the event of any default hereunder, the non-defaulting party may proceed to protect and enforce its rights either by suit in
equity and/or by action at law, including but not limited to an action for damages as a result of any such default, and/or an action
for specific performance for any default where Warrantholder will not have an adequate remedy at law and where damages will not
be readily ascertainable. The Company expressly agrees that it shall not oppose an application by the Warrantholder or any other
person entitled to the benefit of this Agreement requiring specific performance of any or all provisions hereof or enjoining the
Company from continuing to commit any such breach of this Agreement.

 

(c)          No
Impairment of Rights. The Company will not, by amendment of its Charter or through any other means, avoid or seek to avoid
the observance or performance of any of the terms of this Agreement, but will at all times in good faith assist in the carrying
out of all such terms and in the taking of all such actions as may be necessary or appropriate in order to protect the rights of
the Warrantholder against impairment.

 

(d)          [Intentionally
omitted.]

 

(e)          Attorney’s
Fees. In any litigation, arbitration or court proceeding between the Company and the Warrantholder relating hereto, the prevailing
party shall be entitled to attorneys’ fees and expenses and all costs of proceedings incurred in enforcing this Agreement.
For the purposes of this Section 12(e), attorneys’ fees shall include without limitation fees incurred in connection with
the following: (i) contempt proceedings; (ii) discovery; (iii) any motion, proceeding or other activity of any kind in connection
with an insolvency proceeding; (iv) garnishment, levy, and debtor and third party examinations; and (v) post-judgment motions and
proceedings of any kind, including without limitation any activity taken to collect or enforce any judgment.

 

(f)          Severability.
In the event any one or more of the provisions of this Agreement shall for any reason be held invalid, illegal or unenforceable,
the remaining provisions of this Agreement shall be unimpaired, and the invalid, illegal or unenforceable provision shall be replaced
by a mutually acceptable valid, legal and enforceable provision, which comes closest to the intention of the parties underlying
the invalid, illegal or unenforceable provision.

 

(g)          Notices.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other communication
that is required, contemplated, or permitted under this Agreement or with respect to the subject matter hereof shall be in writing,
and shall be deemed to have been validly served, given, delivered, and received upon the earlier of: (i) the day of transmission
by facsimile or hand delivery if transmission or delivery occurs on a business day at or before 5:00 pm in the time zone of the
recipient, or, if transmission or delivery occurs on a non-business day or after such time, the first business day thereafter,
or the first business day after deposit with an overnight express service or overnight mail delivery service; or (ii) the
third calendar day after deposit in the United States mails, with proper first class postage prepaid, and shall be addressed to
the party to be notified as follows:

 

    	8

    	 

    

 

If to Warrantholder:

[*]

Legal Department

Attention: [*]

[*]

[*]

Facsimile: [*]

Telephone: [*]

 

If to the Company:

Neuralstem, Inc.

Attention: Richard Garr

9700 Great Seneca Parkway

Rockville, MD 20850

Facsimile: 301-560-6634

Telephone: 240-475-3148

 

or to such other address as each party may designate for itself
by like notice.

 

(h)          Entire
Agreement; Amendments. This Agreement constitute the entire agreement and understanding of the parties hereto in respect of
the subject matter hereof, and supersede and replace in their entirety any prior proposals, term sheets, letters, negotiations
or other documents or agreements, whether written or oral, with respect to the subject matter hereof. None of the terms of this
Agreement may be amended except by an instrument executed by each of the parties hereto.

 

(i)          Headings.
The various headings in this Agreement are inserted for convenience only and shall not affect the meaning or interpretation of
this Agreement or any provisions hereof.

 

(j)          Advice
of Counsel. Each of the parties represents to each other party hereto that it has discussed (or had an opportunity to discuss)
with its counsel this Agreement and, specifically, the provisions of Sections 12(n), 12(o), 12(p). 12(q) and 12(r).

 

(k)          No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the
event an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the
parties hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship
of any provisions of this Agreement.

 

(l)          No
Waiver. No omission or delay by Warrantholder at any time to enforce any right or remedy reserved to it, or to require performance
of any of the terms, covenants or provisions hereof by the Company at any time designated, shall be a waiver of any such right
or remedy to which Warrantholder is entitled, nor shall it in any way affect the right of Warrantholder to enforce such provisions
thereafter.

 

(m)          Survival.
All agreements, representations and warranties contained in this Agreement or in any document delivered pursuant hereto shall be
for the benefit of Warrantholder and shall survive the execution and delivery of this Agreement and the expiration or other termination
of this Agreement.

 

(n)          Governing
Law. This Agreement has been negotiated and delivered to Warrantholder in the State of California, and shall have been accepted
by Warrantholder in the State of California. Delivery of Common Stock to Warrantholder by the Company under this Agreement is due
in the State of California. This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the
State of California, excluding conflict of laws principles that would cause the application of laws of any other jurisdiction.

 

    	9

    	 

    

 

(o)          Consent
to Jurisdiction and Venue. All judicial proceedings arising in or under or related to this Agreement may be brought in any
state or federal court of competent jurisdiction located in the State of California. By execution and delivery of this Agreement,
each party hereto generally and unconditionally: (a) consents to personal jurisdiction in Santa Clara County, State of California;
(b) waives any objection as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense
based on lack of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered
thereby in connection with this Agreement. Service of process on any party hereto in any action arising out of or relating to this
Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 12(g), and shall be deemed
effective and received as set forth in Section 12(g). Nothing herein shall affect the right to serve process in any other manner
permitted by law or shall limit the right of either party to bring proceedings in the courts of any other jurisdiction.

 

(p)          Mutual
Waiver of Jury Trial. Because disputes arising in connection with complex financial transactions are most quickly and economically
resolved by an experienced and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration
rules), the parties desire that their disputes be resolved by a judge applying such applicable laws. EACH OF THE COMPANY AND WARRANTHOLDER
SPECIFICALLY WAIVES ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY
CLAIM OR ANY OTHER CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY THE COMPANY AGAINST WARRANTHOLDER OR ITS ASSIGNEE OR
BY WARRANTHOLDER OR ITS ASSIGNEE AGAINST THE COMPANY. This waiver extends to all such Claims, including Claims that involve Persons
other than Borrower and Lender; Claims that arise out of or are in any way connected to the relationship between the Company and
Warrantholder; and any Claims for damages, breach of contract, specific performance, or any equitable or legal relief of any kind,
arising out of this Agreement.

 

(q)          Judicial
Reference. If the waiver of jury trial set forth above is ineffective or unenforceable, the parties agree that all Claims shall
be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a mutually
acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of Santa Clara County, California.
Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery applicable
to such proceeding.

 

(r)          Prejudgment
Relief. In the event Claims are to be resolved by arbitration, either party may seek from a court of competent jurisdiction
identified in Section 12(o), any prejudgment order, writ or other relief and have such prejudgment order, writ or other relief
enforced to the fullest extent permitted by law notwithstanding that all Claims are otherwise subject to resolution by judicial
reference.

 

(s)          Counterparts.
This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by
different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which
counterparts shall constitute but one and the same instrument.

 

(t)          Specific
Performance. The parties hereto hereby declare that it is impossible to measure in money the damages which will accrue to Warrantholder
by reason of the Company’s failure to perform any of the obligations under this Agreement and agree that the terms of this
Agreement shall be specifically enforceable by Warrantholder. If Warrantholder institutes any action or proceeding to specifically
enforce the provisions hereof, any person against whom such action or proceeding is brought hereby waives the claim or defense
therein that Warrantholder has an adequate remedy at law, and such person shall not offer in any such action or proceeding the
claim or defense that such remedy at law exists.

 

[Remainder of Page Intentionally Left Blank]

 

    	10

    	 

    

 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement
to be executed by its officers thereunto duly authorized as of the Effective Date.

 

	COMPANY:	NEURALSTEM, INC.
	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 
	 	 
	WARRANTHOLDER:	[*]
	 	 
	 	By:	 
	 	Name: 	[*]
	 	Title: 	[*]

 

    	11

    	 

    

 

EXHIBIT I

 

NOTICE OF EXERCISE

 

		To:	NEURALSTEM, INC.

 

		(1)	The undersigned Warrantholder hereby elects to purchase
[_______] shares of the Common Stock of Neuralstem, Inc., pursuant to the terms of the Agreement dated the 22nd day of March,
2013 (the “Agreement”) between Neuralstem, Inc. and the Warrantholder, and [CASH PAYMENT: tenders herewith payment
of the Purchase Price in full, together with all applicable transfer taxes, if any.] [NET ISSUANCE: elects pursuant to Section 3(a)
of the Agreement to effect a Net Issuance.]

 

		(2)	Please issue a certificate or certificates representing
said shares of Common Stock in the name of the undersigned or in such other name as is specified below.

 

	 	 
	 	(Name)
	 	 
	 	 
	 	(Address)
	 	 
	WARRANTHOLDER:	[*]
	 	 	 
	 	By:	 
	 	Name: 	 
	 	Title:	 
	 	Date:	 

 

    	12

    	 

    

 

EXHIBIT II

 

ACKNOWLEDGMENT OF EXERCISE

 

The undersigned Neuralstem, Inc., hereby acknowledge receipt
of the “Notice of Exercise” from [*] to purchase [____] shares of the Common Stock of Neuralstem, Inc., pursuant to
the terms of the Agreement, and further acknowledges that [______] shares remain subject to purchase under the terms of the Agreement.

 

	 	COMPANY:	NEURALSTEM, INC.
	 	 	 
	 	 	By:	 
	 	 	 	 
	 	 	Title:	 
	 	 	 	 
	 	 	Date: 	 

 

    	13

    	 

    

 

EXHIBIT III

 

TRANSFER NOTICE

 

(To transfer or assign the foregoing Agreement, execute this
form and supply required information. Do not use this form to purchase shares.)

 

FOR VALUE RECEIVED, the foregoing Agreement and all rights evidenced
thereby are hereby transferred and assigned to

 

	 	 
	(Please Print)	 
	 	 
	whose address is 	 	 
	 	 
	 	 

  

 

	 	Dated:	 

 

	 	Holder’s Signature: 	 
	 	 	 
	 	Holder’s Address:	 
	 	 
	 	 

  

 

	Signature Guaranteed: 	 	 

 

NOTE:  The signature to this Transfer Notice must
correspond with the name as it appears on the face of the Agreement, without alteration or enlargement or any change whatever.
Officers of corporations and those acting in a fiduciary or other representative capacity should file proper evidence of authority
to assign the foregoing Agreement.

 

    	14LOAN
AND SECURITY AGREEMENT 

 

THIS LOAN AND
SECURITY AGREEMENT is made and dated as of March 22, 2013 and is entered into by and between NEURALSTEM, INC., a Delaware corporation,
and each of its subsidiaries, (hereinafter collectively referred to as the “Borrower”), and HERCULES TECHNOLOGY III,
L.P., a Delaware limited partnership (“Lender”).

 

RECITALS

 

A.           Borrower
has requested Lender to make available to Borrower a loan in an aggregate principal amount of up to Ten Million Dollars ($10,000,000.00)
(the "Term Loan");

 

B.           Lender
is willing to make the Term Loan on the terms and conditions set forth in this Agreement.

 

AGREEMENT

 

NOW, THEREFORE,
Borrower and Lender agree as follows:

 

SECTION
1. DEFINITIONS AND RULES OF CONSTRUCTION

 

1.1           Unless
otherwise defined herein, the following capitalized terms shall have the following meanings:

 

“Account
Control Agreement(s)” means any agreement entered into by and among the Lender, Borrower and a third party Bank or other
institution (including a Securities Intermediary) in which Borrower maintains a Deposit Account or an account holding Investment
Property and which grants Lender a perfected first priority security interest in the subject account or accounts.

 

“ACH Authorization”
means the ACH Debit Authorization Agreement in substantially the form of Exhibit I.

 

“Advance(s)”
means a Term Loan Advance.

 

“Advance
Date” means the funding date of any Advance.

 

“Advance
Request” means a request for an Advance submitted by Borrower to Lender in substantially the form of Exhibit A.

 

“Agreement”
means this Loan and Security Agreement, as amended from time to time.

 

“Assignee”
has the meaning given to it in Section 11.13.

 

    	1

    	 

    

  

“Borrower
Products” means all products, software, service offerings, technical data or technology currently being designed, manufactured
or sold by Borrower or which Borrower intends to sell, license, or distribute in the future including any products or service
offerings under development, collectively, together with all products, software, service offerings, technical data or technology
that have been sold, licensed or distributed by Borrower since its incorporation.

 

“Cash”
means all cash and liquid funds.

 

“Change
in Control” means any (i) reorganization, recapitalization, consolidation or merger (or similar transaction or series of
related transactions) of Borrower or any Subsidiary, sale or exchange of outstanding shares (or similar transaction or series
of related transactions) of Borrower or any Subsidiary in which the holders of Borrower or Subsidiary’s outstanding shares
immediately before consummation of such transaction or series of related transactions do not, immediately after consummation of
such transaction or series of related transactions, retain shares representing more than fifty percent (50%) of the voting power
of the surviving entity of such transaction or series of related transactions (or the parent of such surviving entity if such
surviving entity is wholly owned by such parent), in each case without regard to whether Borrower or Subsidiary is the surviving
entity, or (ii) sale or issuance by Borrower of new shares of Preferred Stock of Borrower
to investors, none of whom are current investors in Borrower, and such new shares of Preferred Stock are senior to all existing
Preferred Stock and Common Stock with respect to liquidation preferences, and the aggregate liquidation preference of the new
shares of Preferred Stock is more than fifty percent (50%) of the aggregate liquidation preference of all shares of Preferred
Stock of Borrower. 

 

“Claims”
has the meaning given to it in Section 11.10.

 

“Closing
Date” means the date of this Agreement.

 

“Collateral”
means the property described in Section 3.

 

“Commitment
Fee” means $37,500.00, which fee is due to Lender on or prior to the Closing Date, and shall be deemed fully earned on such
date regardless of the early termination of this Agreement.

 

“Confidential
Information” has the meaning given to it in Section 11.12.

 

“Contingent
Obligation” means, as applied to any Person, any direct or indirect liability, contingent or otherwise, of that Person with
respect to (i) any indebtedness, lease, dividend, letter of credit or other obligation of another, including any such obligation
directly or indirectly guaranteed, endorsed, co-made or discounted or sold with recourse by that Person, or in respect of which
that Person is otherwise directly or indirectly liable; (ii) any obligations with respect to undrawn letters of credit, corporate
credit cards, any obligations with respect to the financing of insurance premiums, or merchant services issued for the account
of that Person; and (iii) all obligations arising under any interest rate, currency or commodity swap agreement, interest rate
cap agreement, interest rate collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation
in interest rates, currency exchange rates or commodity prices; provided, however, that the term “Contingent Obligation”
shall not include endorsements for collection or deposit in the ordinary course of business. The amount of any Contingent Obligation
shall be deemed to be an amount equal to the stated or determined amount of the primary obligation in respect of which such Contingent
Obligation is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof as determined
by such Person in good faith; provided, however, that such amount shall not in any event exceed the maximum amount of the obligations
under the guarantee or other support arrangement.

 

    	2

    	 

    

  

“Copyright
License” means any written agreement granting any right to use any Copyright or Copyright registration, now owned or hereafter
acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

“Copyrights”
means all copyrights, whether registered or unregistered, held pursuant to the laws of the United States, any State thereof, or
of any other country.

 

“Deposit
Accounts” means any “deposit accounts,” as such term is defined in the UCC, and includes any checking account,
savings account, or certificate of deposit.

 

“ERISA”
is the Employee Retirement Income Security Act of 1974, and its regulations.

 

“Event of
Default” has the meaning given to it in Section 9.

 

“Facility
Charge” means $100,000, representing one percent (1.0%) of the Maximum Term Loan Amount.

 

“Financial
Statements” has the meaning given to it in Section 7.1.

 

“GAAP”
means generally accepted accounting principles in the United States of America, as in effect from time to time.

 

“Indebtedness”
means indebtedness of any kind, including (a) all indebtedness for borrowed money or the deferred purchase price of property or
services (excluding trade credit entered into in the ordinary course of business due within sixty (60) days), including reimbursement
and other obligations with respect to surety bonds and letters of credit, (b) all obligations evidenced by notes, bonds, debentures
or similar instruments, (c) all capital lease obligations, and (d) all Contingent Obligations.

 

“Insolvency
Proceeding” is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy
or insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors,
or proceedings seeking reorganization, arrangement, or other relief.

 

“Intellectual
Property” means all of Borrower’s Copyrights; Trademarks; Patents; Licenses; trade secrets and inventions; design
rights, mask works; Borrower’s applications therefor and reissues, extensions, or renewals thereof; and Borrower’s
goodwill associated with any of the foregoing, together with Borrower’s rights to sue for past, present and future infringement
of Intellectual Property and the goodwill associated therewith.

 

    	3

    	 

    

 

“Interest-Only
Period” means the period beginning on the Closing Date and expiring on December 1, 2013, provided the Interest-Only Period
shall be the period beginning on the Closing Date and expiring on March 1, 2014 if Borrower draws the Second Advance on or before
September 30, 2013.

 

“Investment”
means any beneficial ownership (including stock, partnership or limited liability company interests) of or in any Person, or any
loan, advance or capital contribution to any Person or the acquisition of all, or substantially all, of the assets of another
Person.

 

“Joinder
Agreements” means for each Subsidiary, a completed and executed Joinder Agreement in substantially the form attached hereto
as Exhibit G.

 

“Lender”
has the meaning given to it in the preamble to this Agreement.

 

“License”
means any Copyright License, Patent License, Trademark License or other license of rights or interests.

 

“Lien”
means any mortgage, deed of trust, pledge, hypothecation, assignment for security, security interest, encumbrance, levy, lien
or charge of any kind, whether voluntarily incurred or arising by operation of law or otherwise, against any property, any conditional
sale or other title retention agreement, and any lease in the nature of a security interest.

 

“Loan”
means the Advances made under this Agreement.

 

“Loan Documents”
means this Agreement, the Notes (if any), the Intellectual Property Security Agreement, the ACH Authorization, the Account Control
Agreements, the Joinder Agreements, all UCC Financing Statements, the Warrant, and any other documents executed in connection
with the Secured Obligations or the transactions contemplated hereby, as the same may from time to time be amended, modified,
supplemented or restated.

 

“Material
Adverse Effect” means a material adverse effect upon: (i) the business, operations, properties, assets, or condition
(financial or otherwise) of Borrower and its Subsidiaries, taken as a whole; or (ii) the ability of Borrower to perform the
Secured Obligations in accordance with the terms of the Loan Documents, or the ability of Lender to enforce any of its rights
or remedies with respect to the Secured Obligations; or (iii) the Collateral or Lender’s Liens on the Collateral or the
priority of such Liens.

 

“Maximum
Term Loan Amount” means Ten Million and No/100 Dollars ($10,000,000.00).

 

“Maximum
Rate” shall have the meaning assigned to such term in Section 2.2.

 

“Note”
means a Term Note.

 

“Patent
License” means any written agreement granting any right with respect to any invention on which a Patent is in existence
or a Patent application is pending, in which agreement Borrower now holds or hereafter acquires any interest.

 

    	4

    	 

    

  

“Patents”
means all letters patent of, or rights corresponding thereto, in the United States or in any other country, all registrations
and recordings thereof, and all applications for letters patent of, or rights corresponding thereto, in the United States or any
other country.

 

“Permitted
Indebtedness” means: (i) Indebtedness of Borrower in favor of Lender arising under this Agreement or any other Loan Document;
(ii) Indebtedness existing on the Closing Date which is disclosed in Schedule 1A; (iii) Indebtedness of up to $250,000 outstanding
at any time secured by a lien described in clause (vii) of the defined term “Permitted Liens,” provided such Indebtedness
does not exceed the lesser of the cost or fair market value of the Equipment financed with such Indebtedness; (iv) Indebtedness
to trade creditors incurred in the ordinary course of business, including Indebtedness incurred in the ordinary course of business
with corporate credit cards and with respect to the financing of insurance premiums; (v) Indebtedness that also constitutes a
Permitted Investment; (vi) Subordinated Indebtedness; (vii) reimbursement obligations in connection with letters of credit that
are secured by cash or cash equivalents and issued on behalf of the Borrower or a Subsidiary thereof in an amount not to exceed
$200,000 at any time outstanding, (viii) other Indebtedness in an amount not to exceed $250,000 at any time outstanding, and (ix)
extensions, refinancings and renewals of any items of Permitted Indebtedness, provided that the principal amount is not increased
or the terms modified to impose materially more burdensome terms upon Borrower or its Subsidiary, as the case may be.

 

“Permitted
Investment” means: (i) Investments existing on the Closing Date which are disclosed in Schedule 1B; (ii) (a) marketable
direct obligations issued or unconditionally guaranteed by the United States of America or any agency or any State thereof maturing
within one year from the date of acquisition thereof, (b) commercial paper maturing no more than one year from the date of creation
thereof and currently having a rating of at least A-2 or P-2 from either Standard & Poor’s Corporation or Moody’s
Investors Service, (c) certificates of deposit issued by any bank with assets of at least $500,000,000 maturing no more than one
year from the date of investment therein, and (d) money market accounts; (iii) repurchases of stock from former employees, directors,
or consultants of Borrower under the terms of applicable repurchase agreements at the original issuance price of such securities
in an aggregate amount not to exceed $250,000 in any fiscal year, provided that no Event of Default has occurred, is continuing
or would exist after giving effect to the repurchases; (iv) Investments accepted in connection with Permitted Transfers; (v) Investments
(including debt obligations) received in connection with the bankruptcy or reorganization of customers or suppliers and in settlement
of delinquent obligations of, and other disputes with, customers or suppliers arising in the ordinary course of Borrower’s
business; (vi) Investments consisting of notes receivable of, or prepaid royalties and other credit extensions, to customers and
suppliers who are not affiliates, in the ordinary course of business, provided that this subparagraph (vi) shall not apply to
Investments of Borrower in any Subsidiary; (vii) Investments consisting of loans
not involving the net transfer on a substantially contemporaneous basis of cash proceeds to employees, officers or directors relating
to the purchase of capital stock of Borrower pursuant to employee stock purchase plans or other similar agreements approved by
Borrower’s Board of Directors; (viii) Investments consisting of travel advances in the ordinary course of business;
(ix) Investments in newly-formed Subsidiaries organized in the United States, provided
that such Subsidiaries enter into a Joinder Agreement promptly after their formation by Borrower and execute such other documents
as shall be reasonably requested by Lender; (x) Investments in Subsidiaries organized outside of the United States approved in
advance in writing by Lender provided that no such written approval will be required with regard to any Subsidiary existing on
the Closing Date as disclosed on Schedule 1B; (xi) Investments in Subsidiaries planned for formation outside of the
United States that are identified on Schedule 1B, so long as (A) Borrower delivers written notice to Lender concurrently with
the formation of each such Subsidiary, (B) Borrower delivers a certificate for 65% of the stock of such entity and takes such
other steps as Lender may require to enable Lender to perfect its security interest, and (C) Borrower’s cash Investment
in such Subsidiary or Subsidiaries does not exceed 110% of the amounts shown on Schedule 1B; and (xii) joint ventures or strategic
alliances in the ordinary course of Borrower’s business consisting of the nonexclusive (except to the extent disclosed on
Schedule 1B) licensing of technology, the development of technology, providing of technical support, or consisting of the contribution
of products derived from the Borrower’s Intellectual Property, provided that any cash Investments by Borrower do not exceed
$100,000 in the aggregate in any fiscal year.

 

    	5

    	 

    

  

“Permitted
Liens” means any and all of the following: (i) Liens in favor of Lender; (ii) Liens existing on the Closing Date which are
disclosed in Schedule 1C; (iii) Liens for taxes, fees, assessments or other governmental charges or levies, either not delinquent
or being contested in good faith by appropriate proceedings; provided, that Borrower maintains adequate reserves therefor in accordance
with GAAP; (iv) Liens securing claims or demands of materialmen, artisans, mechanics, carriers, warehousemen, landlords and
other like Persons arising in the ordinary course of Borrower’s business and imposed without action of such parties; provided,
that the payment thereof is not yet required; (v) Liens arising from judgments, decrees or attachments in circumstances which
do not constitute an Event of Default hereunder; (vi) the following deposits, to the extent made in the ordinary course of
business: deposits under worker’s compensation, unemployment insurance, social security and other similar laws, or to secure
the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to secure indemnity, performance
or other similar bonds for the performance of bids, tenders or contracts (other than for the repayment of borrowed money) or to
secure statutory obligations (other than liens arising under ERISA or environmental liens) or surety or appeal bonds, or to secure
indemnity, performance or other similar bonds; (vii) Liens on Equipment or software or other intellectual property constituting
purchase money liens and liens in connection with capital leases securing Indebtedness permitted in clause (iii) of “Permitted
Indebtedness”; (viii) Liens incurred in connection with Subordinated Indebtedness; (ix) leasehold interests in leases or
subleases and licenses granted in the ordinary course of business and not interfering in any material respect with the business
of the licensor; (x) Liens in favor of customs and revenue authorities arising as a matter of law to secure payment of custom
duties that are promptly paid on or before the date they become due; (xi) Liens on insurance proceeds securing the payment of
financed insurance premiums that are promptly paid on or before the date they become due (provided that such Liens extend only
to such insurance proceeds and not to any other property or assets); (xii) statutory and common law rights of set-off and other
similar rights as to deposits of cash and securities in favor of banks, other depository institutions and brokerage firms; (xiii)
easements, zoning restrictions, rights-of-way and similar encumbrances on real property imposed by law or arising in the ordinary
course of business so long as they do not materially impair the value or marketability of the related property; (xiv) Liens on
cash or cash equivalents securing obligations permitted under clause (vii) of the definition of Permitted Indebtedness; and (xv)
Liens incurred in connection with the extension, renewal or refinancing of the indebtedness secured by Liens of the type described
in clauses (i) through (xi) above; provided, that any extension, renewal or replacement Lien shall be limited to the property
encumbered by the existing Lien and the principal amount of the indebtedness being extended, renewed or refinanced (as may have
been reduced by any payment thereon) does not increase.

 

    	6

    	 

    

  

“Permitted
Transfers” means (i) sales of Inventory, (including but not limited to stem cell inventory, equipment and products derived
from the Company’s intellectual property and other technology and know-how to various joint ventures or collaborative efforts),
in the normal course of business, (ii) non-exclusive (except to the extent disclosed on Schedule 1B) licenses and similar arrangements
for the use of Intellectual Property in the ordinary course of business and licenses that could not result in a legal transfer
of title of the licensed property but that may be exclusive in respects other than territory and that may be exclusive as to territory
only as to discreet geographical areas outside of the United States in the ordinary course of business, or (iii) dispositions
of worn-out, obsolete or surplus Equipment at fair market value in the ordinary course of business, (iv) Transfers made in accordance
with Permitted Investments and (v) other Transfers of assets not contained in (i), (ii), (iii) and (iv) above having a fair market
value of not more than $250,000 in the aggregate in any fiscal year.

 

“Person”
means any individual, sole proprietorship, partnership, joint venture, trust, unincorporated organization, association, corporation,
limited liability company, institution, other entity or government.

 

“Preferred
Stock” means at any given time any equity security issued by Borrower that has any rights, preferences or privileges senior
to Borrower’s common stock.

 

“Prepayment
Charge” shall have the meaning assigned to such term in Section 2.4.

 

“Receivables”
means (i) all of Borrower’s Accounts, Instruments, Documents, Chattel Paper, Supporting Obligations, letters of credit,
proceeds of any letter of credit, and Letter of Credit Rights, and (ii) all customer lists, software, and business records related
thereto.

 

“SBA”
shall have the meaning assigned to such term in Section 7.14.

 

“SBIC”
shall have the meaning assigned to such term in Section 7.14.

 

“SBIC Act”
shall have the meaning assigned to such term in Section 7.14.

 

“Secured
Obligations” means Borrower’s obligations under this Agreement and any
Loan Document, but specifically excluding the Warrant, including any obligation to pay any amount now owing or later arising.

 

“Subordinated
Indebtedness” means Indebtedness subordinated to the Secured Obligations in amounts and on terms and conditions satisfactory
to Lender in its sole discretion.

 

“Subsequent
Financing” means the closing of any Borrower financing which becomes effective after the Closing Date but before the repayment
of the Secured Obligations and results in aggregate proceeds to Borrower of at least $10,000,000.

 

    	7

    	 

    

  

“Subsidiary”
means an entity, whether corporate, partnership, limited liability company, joint venture or otherwise, in which Borrower owns
or controls 50% or more of the outstanding voting securities, including each entity listed on Schedule 1 hereto.

 

“Term Loan
Advance” means any Term Loan funds advanced pursuant to this Agreement.

 

“Term Loan
Interest Rate” means for any day a per annum rate of interest equal to the greater of either (i) 11.0% plus the prime rate
as reported in The Wall Street Journal minus 3.25%, or (ii) 11.0%.

 

“Term Loan
Maturity Date” means June 1, 2016, provided Term Loan Maturity Date shall be September 1, 2016 if the Interest-Only Period
is extended pursuant to Section 2.1.

 

“Term Note”
means a Promissory Note in substantially the form of Exhibit B.

 

“Trademark
License” means any written agreement granting any right to use any Trademark or Trademark registration, now owned or hereafter
acquired by Borrower or in which Borrower now holds or hereafter acquires any interest.

 

“Trademarks”
means all trademarks (registered, common law or otherwise) and any applications in connection therewith, including registrations,
recordings and applications in the United States Patent and Trademark Office or in any similar office or agency of the United
States, any State thereof or any other country or any political subdivision thereof.

 

“UCC”
means the Uniform Commercial Code as the same is, from time to time, in effect in the State of California; provided, that in the
event that, by reason of mandatory provisions of law, any or all of the attachment, perfection or priority of, or remedies with
respect to, Lender’s Lien on any Collateral is governed by the Uniform Commercial Code as the same is, from time to time,
in effect in a jurisdiction other than the State of California, then the term “UCC” shall mean the Uniform Commercial
Code as in effect, from time to time, in such other jurisdiction solely for purposes of the provisions thereof relating to such
attachment, perfection, priority or remedies and for purposes of definitions related to such provisions.

 

“Warrant”
means the warrant entered into in connection with the Loan.

 

Unless otherwise
specified, all references in this Agreement or any Annex or Schedule hereto to a “Section,” “subsection,”
“Exhibit,” “Annex,” or “Schedule” shall refer to the corresponding Section, subsection, Exhibit,
Annex, or Schedule in or to this Agreement. Unless otherwise specifically provided herein, any accounting term used in this Agreement
or the other Loan Documents shall have the meaning customarily given such term in accordance with GAAP, and all financial computations
hereunder shall be computed in accordance with GAAP, consistently applied. Unless otherwise defined herein or in the other Loan
Documents, terms that are used herein or in the other Loan Documents and defined in the UCC shall have the meanings given to them
in the UCC.

 

    	8

    	 

    

  

SECTION
2. THE LOAN

 

2.1           Term
Loan.

 

(a)          Advances.
Subject to the terms and conditions of this Agreement, Lender will make, and Borrower agrees to draw, two Term Loan Advances,
the first in a principal amount equal to $8,000,000 on the Closing Date, and the second in a principal amount of $2,000,000 at
any time after Borrower satisfies the second advance conditions set forth in Section 2.1(b), but in any case not later than September
30, 2013.

 

(b)          Second
Advance Conditions. As a condition to requesting the second Term Loan Advance, (i) Borrower shall present Lender with evidence
satisfactory to Lender of the close of partnerships reasonably satisfactory to Lender generating not less than $4,500,000 in up-front
cash proceeds, (ii) all of the representations and warranties set forth in Section 5 shall be true in all material respects, and
(iii) an Event of Default shall not then be continuing.

 

(c)          Advance
Request. To obtain a Term Loan Advance, Borrower shall complete, sign and deliver an Advance Request (at least five business days
before the Advance Date) to Lender. Lender shall fund the Term Loan Advance in the manner requested by the Advance Request provided
that each of the conditions precedent to such Term Loan Advance is satisfied as of the requested Advance Date.

 

(d)          Interest.
The principal balance of a Term Loan Advance shall bear interest thereon from such Advance Date at the Term Loan Interest Rate
based on a year consisting of 360 days, with interest computed daily based on the actual number of days elapsed. The Term Loan
Interest Rate will float and change on the day the Prime Rate changes from time to time.

 

(e)          Payment.
Borrower will pay interest on each Term Loan Advance on the first day of each month, beginning the month after the Advance Date
and continuing during the Interest-Only Period. Beginning on the first day of the month following the expiration of the Interest-Only
Period, Borrower shall repay the aggregate Term Loan principal balance that is outstanding on such date in 30 equal monthly installments
of principal and interest (mortgage style). The entire Term Loan principal balance and all accrued but unpaid interest shall be
due and payable on Term Loan Maturity Date. Borrower shall make all payments under this Agreement without setoff, recoupment or
deduction and regardless of any counterclaim or defense. Lender will initiate debit entries to Borrower’s account as authorized
on the ACH Authorization on each payment date of all periodic obligations payable under this Agreement or the Term Note.

 

(f)          Optional
Payment in Cash or Conversion to Common Stock of Monthly Amount or Prepayment Principal Amount. 

 

    	9

    	 

    

 

(i)          Borrower
Election for Payment in Cash or Conversion to Common Stock. Subject to satisfaction of the Conversion Conditions and compliance
with the other terms and conditions of this Section 2.1(f) Borrower may elect to pay, in whole or in part, any regularly scheduled
installment of principal (a “Principal Installment Payment”) up to an aggregate maximum amount of $1,000,000 by converting
a portion of the principal of the Note into shares of Common Stock in lieu of payment in cash (such option, the “Conversion
Option”). In order to validly exercise a Conversion Option, Borrower (A) must deliver written notice thereof, in the form
attached hereto as Exhibit I, to Lender (a “Conversion Election Notice”) five (5) days prior to the
applicable due date of the Principal Installment Payment (the “Principal Installment Due Date”) and (B) shall (provided
that Borrower’s transfer agent is participating in the Fast Automated Securities Transfer Program of the Depository Trust
Company) credit to Lender by no later than the first trading day following the applicable Principal Installment Due Date (such
date, the “Delivery Date”) such aggregate number of shares of Common Stock to be issued to Lender with respect to
such Conversion Election Notice, as determined in accordance with this Section 2.1(f) (which shares shall be free of any restrictions
on transfer), by no later than the first trading day following the applicable Delivery Date. All payments in respect of a Principal
Installment Payment shall be made in cash, unless (i) Borrower timely delivers a Conversion Election Notice in accordance with
the immediately preceding sentence, (ii) Borrower timely credits the shares of Common Stock to Lender, free of restrictive legends,
in accordance with this Section 2.1(f) and (iii) the Conversion Conditions are satisfied in respect of such payment. A Conversion
Election Notice, once delivered by Borrower, shall be irrevocable unless otherwise agreed, in writing, by Lender. If Borrower
elects to make a Principal Installment Payment, in whole or in part, through conversion of such amount into shares of Common Stock,
the number of such shares of Common Stock to be issued in respect of such Principal Installment Payment shall be equal to the
number determined by dividing (x) the principal amount to be paid in shares of Common Stock by (y) the Fixed Conversion Price.
For purposes hereof, the “Fixed Conversion Price” shall be the price which is 15% higher than the applicable Exercise
Price (as defined in the Warrant); provided, however, that upon the occurrence of any stock split, stock dividend, combination
of shares or reverse stock split pertaining to the Common Stock, the Fixed Conversion Price shall be proportionately increased
or decreased as necessary to reflect the proportionate change in the shares of Common Stock issued and outstanding as a result
of such stock split, stock dividend, combination of shares or reverse stock split. Any shares of Common Stock issued pursuant
to a Conversion Election Notice shall be deemed to be issued upon conversion of the Note.

 

    	10

    	 

    

 

(ii)         Conversion
Conditions. Notwithstanding the foregoing, Borrower’s right to deliver, and Lender’s obligation to accept, shares
of Common Stock in lieu of payment in cash of a Principal Installment Payment is conditioned on the satisfaction of each of the
following conditions (the “Conversion Conditions”) as of such Delivery Date: (A) the closing price of the shares of
Common Stock as reported by Bloomberg, L.P. on the NYSE MKT stock market (the “NYSE MKT”) for each of the seven (7)
consecutive trading days immediately preceding the Delivery Date shall be greater than or equal to the Fixed Conversion Price;
(B) the Common Stock issued in connection with any such payment does not exceed 15% of the total trading volume of the Common
Stock for the twenty-two (22) consecutive trading days immediately prior to and including such Delivery Date; (C) only
one Conversion Election Notice may be given in any calendar month during the amortization period; (D) the aggregate principal
amount to be paid in shares of Common Stock pursuant to Section 2.1(f)(i) of this Agreement shall not exceed One Million Dollars
($1,000,000); (E) the Common Stock is (and was on each of the twenty-two (22) consecutive trading days immediately preceding such
Delivery Date) quoted or listed on the NYSE MKT or other national securities exchange; (F) a registration statement is effective
and available for the resale of all of the shares of Common Stock to be delivered on such Delivery Date, or such shares of Common
Stock are eligible for resale to the public pursuant to Rule 144 without any limitation; (G) after giving effect to the issuance
of such shares of Common Stock to Lender, Lender would not (A) beneficially own, together with its affiliates, Common Stock in
excess of the limitations specified in subsection (f)(iii) below and (B) have been issued shares of Common Stock pursuant to all
Conversion Election Notices in an aggregate amount in excess of the Cap, as defined in subsection (f)(iii) below; (H) as of such
Delivery Date, there is no outstanding Event of Default and there is no breach or default that, if left uncured, would result
in an Event of Default; and (I) Borrower shall have sufficient authorized but unissued shares of Common Stock to provide for the
issuance of the shares of Common Stock pursuant to the Conversion Election Notice. If any of the Conversion Conditions are not
satisfied as of a Delivery Date, Borrower shall not be permitted to pay, and Lender shall not be obligated to accept, the Principal
Installment Payment in shares of Common Stock, and Borrower shall instead pay such principal amount in cash; provided, however,
that the Conversion Conditions set forth in clauses (A), (B), (C), (E), (F) and (H) above may be waived by a writing executed
by both Borrower and Lender. In the event the Company is relying upon an effective registration statement to satisfy clause (F)
of the Conversion Conditions, each of the Company and Lender shall provide customary indemnification to one another with respect
to such registration statement in a form acceptable to the Company and Lender. By no later than the first trading day following
the Delivery Date, Borrower shall (provided that Borrower’s transfer agent is participating in the Fast Automated Securities
Transfer Program of the Depository Trust Company) credit to Lender the shares of Common Stock to be delivered by Borrower with
respect to the portion of the Principal Installment Payment being paid in shares of Common Stock. 

 

    	11

    	 

    

(iii)        Lender
Election for Payment in Cash or Conversion to Common Stock. Subject to satisfaction of the Conversion Conditions and compliance
with the other terms and conditions of this Section 2.1(f), with respect to any Principal Installment Payment scheduled from Borrower,
Lender may elect to receive such payment in Common Stock by requiring Borrower to effect a Conversion Option. In order to effect
such a Conversion Option, Lender shall (A) deliver a Conversion Election Notice to Borrower five (5) days prior to (i) the applicable
Principal Installment Due Date. Borrower shall (provided that Borrower’s transfer agent is participating in the Fast Automated
Securities Transfer Program of the Depository Trust Company) credit to Lender by no later than the Delivery Date such aggregate
number of shares of Common Stock to be issued to Lender with respect to such Conversion Election Notice, as determined in accordance
with this Section 2.1(f) (which shares shall be free of any restrictions on transfer), by no later than the first trading day
following the applicable Delivery Date. A Conversion Election Notice, once delivered by Lender, shall be irrevocable unless otherwise
agreed, in writing, by Borrower. If Lender elects to receive a Principal Installment Payment in whole or in part, through conversion
of such amount into shares of Common Stock, the number of such shares of Common Stock to be issued in respect of such Principal
Installment Payment shall be equal to the number determined by dividing (x) the principal amount to be paid in shares of Common
Stock by (y) the Fixed Conversion Price; provided, however, that upon the occurrence of any stock split, stock dividend, combination
of shares or reverse stock split pertaining to the Common Stock, the Fixed Conversion Price shall be proportionately increased
or decreased as necessary to reflect the proportionate change in the shares of Common Stock issued and outstanding as a result
of such stock split, stock dividend, combination of shares or reverse stock split. Any shares of Common Stock issued pursuant
to a Conversion Election Notice shall be deemed to be issued upon partial conversion of the principal of the Note. Notwithstanding
the foregoing, Lender’s right to receive, and Borrower’s obligation to issue, shares of Common Stock in lieu of payment
in cash of a Principal Installment Payment is conditioned on the satisfaction of each of the following conditions as of such Delivery
Date: (A) only one Conversion Election Notice may be given in any calendar month during the amortization period; and (B) the aggregate
principal amount to be paid in shares of Common Stock pursuant to Section 2.1(f)(iii) of this Agreement shall not exceed One Million
Dollars ($1,000,000).

 

(iv)        Beneficial
Ownership Limitation. Notwithstanding any provision herein to the contrary, Lender, together with its affiliates, shall not be
permitted to beneficially own a number of shares of Common Stock (other than shares that may be deemed beneficially owned except
for being subject to a limitation analogous to the limitation contained in this Section 2.1(f)(iii)) in excess of 9.99% of the
number of shares of Common Stock then issued and outstanding, it being the intent of Borrower and Lender that Lender, together
with its affiliates, not be deemed at any time to have the power to vote or dispose of greater than 9.99% of the number of shares
of Common Stock issued and outstanding at any time; provided, however, that Lender shall have the right, upon 61
days’ prior written notice to Borrower, to waive the 9.99% limitation of this subsection. Notwithstanding anything contained
herein to the contrary, Borrower shall not be permitted to issue to Lender, and Lender shall not be required to accept, shares
of Common Stock pursuant to a Conversion Election Notice if and to the extent such issuance, when taking together with all other
issuances pursuant to prior Conversion Election Notices, would result in (A) the issuance of more than 19.99% of the Common Stock
outstanding as of the date of this Agreement or (B) Lender, together with its affiliates, beneficially owning in excess of 19.99%
of the outstanding Common Stock (each of clauses (A) and (B) are referred to herein as the “Cap”). As used herein,
beneficial ownership shall be determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended (the
“1934 Act”). For any reason at any time, upon written or oral request of Lender, Borrower shall within one business
day confirm orally and in writing to Lender the number of shares of Common Stock then issued and outstanding as of any given date.

 

    	12

    	 

    

 

 

(v)         Rule
144. With a view to making available to Lender the benefits of Rule 144 (or its successor rule) and any other rule or regulation
of the Securities and Exchange Commission (the “SEC”) that may at any time permit Lender to sell shares of Common
Stock issued pursuant to Section 2.1(f) of this Agreement to the public without registration, Borrower covenants and agrees to:
(i) make and keep public information available, as those terms are understood and defined in Rule 144, until six (6) months after
such date as all of the shares of Common Stock issued pursuant to Section 2.1(f) of this Agreement may be sold without restriction
by Lender pursuant to Rule 144 or any other rule of similar effect; (ii) file with the SEC in a timely manner (or obtain
extensions in respect thereof and file within the applicable grace period) all reports
and other documents required of Borrower under the 1934 Act; and (iii) furnish to Lender upon request, as long as Lender owns
any shares of Common Stock issued pursuant to Section 2.1(f) of this Agreement, such information as may be reasonably requested
in order to avail Lender of any rule or regulation of the SEC that permits the selling of any such shares of Common Stock without
registration.

 

(vi)        Stock
Reservation. Borrower covenants and agrees to reserve from its duly authorized capital stock not less than the number of shares
of Common Stock that may be issuable upon payment of any Principal Installment Payment pursuant to Section 2.1(f) of this Agreement.
Borrower further represents, warrants and covenants that, upon issuance of any shares of Common Stock pursuant to Section 2.1(f)
of this Agreement, such shares of Common Stock shall be validly issued, fully paid and non-assessable and free from all preemptive
or similar rights, taxes, liens and charges with respect to the issue thereof.

 

(vii)       Authorization.
For so long as Lender holds any shares of Common Stock issued pursuant to Section 2.1(f) of this Agreement, Borrower shall maintain
the Common Stock’s authorization for listing on NYSE MKT (or on another national securities exchange) and Borrower shall
not take any action which would reasonably be expected to result in the delisting or suspension of the Common Stock on NYSE MKT
(or other national securities exchange on which the Common Stock is listed).

 

2.2           Maximum
Interest. Notwithstanding any provision in this Agreement or any other Loan Document, it is the parties’ intent not to contract
for, charge or receive interest at a rate that is greater than the maximum rate permissible by law that a court of competent jurisdiction
shall deem applicable hereto (which under the laws of the State of California shall be deemed to be the laws relating to permissible
rates of interest on commercial loans) (the “Maximum Rate”). If a court of competent jurisdiction shall finally determine
that Borrower has actually paid to Lender an amount of interest in excess of the amount that would have been payable if all of
the Secured Obligations had at all times borne interest at the Maximum Rate, then such excess interest actually paid by Borrower
shall be applied as follows: first, to the payment of the Secured Obligations consisting of the outstanding principal; second,
after all principal is repaid, to the payment of Lender’s accrued interest, costs, expenses, professional fees and any other
Secured Obligations; and third, after all Secured Obligations are repaid, the excess (if any) shall be refunded to Borrower.

 

    	13

    	 

    

 

 

2.3           Default
Interest. In the event any payment is not paid on the scheduled payment date, an amount equal to four percent (4%) of the past
due amount shall be payable on demand. In addition, upon the occurrence and during the continuation of an Event of Default hereunder,
all Secured Obligations, including principal, interest, compounded interest, and professional fees, shall bear interest at a rate
per annum equal to the rate set forth in Section 2.1(c) plus four percent (4%) per annum. In the event any interest is not paid
when due hereunder, delinquent interest shall be added to principal and shall bear interest on interest, compounded at the rate
set forth in Section 2.1(c) or Section 2.3, as applicable.

 

2.4           Prepayment.
At its option upon at least 7 business days prior notice to Lender, Borrower may prepay all, but not less than all, of the outstanding
Advances by paying the entire principal balance, all accrued and unpaid interest, together with a prepayment charge equal to the
following percentage of the Advance amount being prepaid: if such Advance amounts are prepaid in any of the first twelve (12)
months following the Closing Date, 3.0%; after twelve (12) months but prior to twenty four (24) months, 2.0%; and thereafter,
1.0% (each, a “Prepayment Charge”). Notwithstanding the above, Borrower at any time prior to the Term Loan Maturity
Date may make a single prepayment of less than all of the outstanding Advances by paying the portion of the principal balance
being prepaid, all accrued and unpaid interest thereon, together with the applicable Prepayment Charge. Borrower agrees that the
Prepayment Charge is a reasonable calculation of Lender’s lost profits in view of the difficulties and impracticality of
determining actual damages resulting from an early repayment of the Advances. Borrower shall prepay the outstanding amount of
all principal and accrued interest through the prepayment date and the Prepayment Charge upon the occurrence of a Change in Control.

 

2.5           End
of Term Charge. On the earliest to occur of (i) the Term Loan Maturity Date, (ii) the date that Borrower prepays the outstanding
Secured Obligations, or (iii) the date that the Secured Obligations become due and payable, Borrower shall pay Lender a charge
of $350,000.00. Notwithstanding the required payment date of such charge, it shall be deemed earned by Lender as of the Closing
Date. For purposes of clarity, no interest shall be payable upon such amount until the occurrence of a condition contained in
sections 2.5 (i), (ii) or (iii).

 

2.6           Notes.
If so requested by Lender by written notice to Borrower, then Borrower shall execute and deliver to Lender (and/or, if applicable
and if so specified in such notice, to any person who is an assignee of Lender pursuant to Section 11.13) (promptly after the
Borrower’s receipt of such notice) a Note or Notes to evidence Lender’s Loans.

 

    	14

    	 

    

  

SECTION
3. SECURITY INTEREST

  

3.1           As
security for the prompt, complete and indefeasible payment when due (whether on the payment dates or otherwise) of all the Secured
Obligations, Borrower grants to Lender a security interest in all of Borrower’s right, title, and interest in and to the
following personal property whether now owned or hereafter acquired (collectively, the “Collateral”): (a) Receivables;
(b) Equipment; (c) Fixtures; (d) General Intangibles (including without limitation Intellectual Property); (e) Inventory; (f)
Investment Property (but excluding thirty-five percent (35%) of the capital stock of any foreign Subsidiary that constitutes a
Permitted Investment); (g) Deposit Accounts; (h) Cash; (i) Goods; and all other tangible and intangible personal property of Borrower
whether now or hereafter owned or existing, leased, consigned by or to, or acquired by, Borrower and wherever located, and any
of Borrower’s property in the possession or under the control of Lender; and, to the extent not otherwise included, all
Proceeds of each of the foregoing and all accessions to, substitutions and replacements for, and rents, profits and products of
each of the foregoing.

 

SECTION
4. CONDITIONS PRECEDENT TO LOAN

 

The obligations
of Lender to make the Loan hereunder are subject to the satisfaction by Borrower of the following conditions:

 

4.1           Initial
Advance. On or prior to the Closing Date, Borrower shall have delivered to Lender the following:

 

(a)          executed
originals of the Loan Documents, Account Control Agreements, and all other documents and instruments reasonably required by Lender
to effectuate the transactions contemplated hereby or to create and perfect the Liens of Lender with respect to all Collateral,
in all cases in form and substance reasonably acceptable to Lender;

 

(b)          certified
copy of resolutions of Borrower’s board of directors evidencing approval of (i) the Loan and other transactions evidenced
by the Loan Documents; and (ii) the Warrant and transactions evidenced thereby;

 

(c)          certified
copies of the Certificate of Incorporation and the Bylaws, as amended through the Closing Date, of Borrower;

 

(d)          a
certificate of good standing for Borrower from its state of incorporation and similar certificates from all other United States
jurisdictions in which it does business and where the failure to be qualified would have a Material Adverse Effect;

 

(e)          payment
of the Facility Charge and reimbursement of Lender’s current expenses reimbursable pursuant to this Agreement, which amounts
may be deducted from the initial Advance; and

 

(f)          such
other documents as Lender may reasonably request.

 

4.2           All
Advances. On each Advance Date:

 

    	15

    	 

    

 

 

(a)          Lender
shall have received (i) an Advance Request for the relevant Advance as required by Section 2.1(b), each duly executed
by Borrower’s Chief Executive Officer or Chief Financial Officer, and (ii) any other documents Lender may reasonably
request.

 

(b)          The
representations and warranties set forth in this Agreement and in Section 5 and in the Warrant shall be true and correct
in all material respects on and as of the Advance Date with the same effect as though made on and as of such date, except to the
extent such representations and warranties expressly relate to an earlier date.

 

(c)          Borrower
shall be in compliance with all the terms and provisions set forth herein and in each other Loan Document on its part to be observed
or performed, and at the time of and immediately after such Advance no Event of Default shall have occurred and be continuing.

 

(d)          Each
Advance Request shall be deemed to constitute a representation and warranty by Borrower on the relevant Advance Date as to the
matters specified in paragraphs (b) and (c) of this Section 4.2 and as to the matters set forth in the Advance Request.

 

4.3           No
Default. As of the Closing Date and each Advance Date, (i) no fact or condition exists that would (or would, with the passage
of time, the giving of notice, or both) constitute an Event of Default and (ii) no event that has had or could reasonably be expected
to have a Material Adverse Effect has occurred and is continuing.

 

SECTION
5. REPRESENTATIONS AND WARRANTIES OF BORROWER

 

Borrower represents
and warrants that:

 

5.1           Corporate
Status. Borrower is a corporation duly organized, legally existing and in good standing under the laws of the State of Delaware,
and is duly qualified as a foreign corporation in all United States jurisdictions in which the nature of its business or location
of its properties require such qualifications and where the failure to be qualified could reasonably be expected to have a Material
Adverse Effect. Borrower’s present name, former names (if any), locations, place of formation, tax identification number,
organizational identification number and other information are correctly set forth in Exhibit C, as may be updated by Borrower
in a written notice (including any Compliance Certificate) provided to Lender after the Closing Date.

 

5.2           Collateral.
Borrower owns the Collateral, free of all Liens, except for Permitted Liens. Borrower has the power and authority to grant to
Lender a Lien in the Collateral as security for the Secured Obligations.

 

    	16

    	 

    

 

5.3           Consents.
Borrower’s execution, delivery and performance of this Agreement and all other Loan Documents, and Borrower’s execution
of the Warrant, (i) have been duly authorized by all necessary corporate action of Borrower, (ii) will not result in
the creation or imposition of any Lien upon the Collateral, other than Permitted Liens and the Liens created by this Agreement
and the other Loan Documents, (iii) do not violate any provisions of Borrower’s Certificate or Articles of Incorporation
(as applicable), bylaws, or any, law, regulation, order, injunction, judgment, decree or writ to which Borrower is subject and
(iv) except as described on Schedule 5.3, do not violate any contract or agreement or require the consent or approval of
any other Person. The individual or individuals executing the Loan Documents and the Warrant are duly authorized to do so.

 

5.4           Material
Adverse Effect. No event that has had or could reasonably be expected to have a Material Adverse Effect has occurred and is continuing.
Borrower is not aware of any event likely to occur that is reasonably expected to result in a Material Adverse Effect.

 

5.5           Actions
Before Governmental Authorities. To the best of the Company’s knowledge, and except as described on Schedule 5.5, there
are no actions, suits or proceedings at law or in equity or by or before any governmental authority now pending or, to the knowledge
of Borrower, threatened against or affecting Borrower or its property.

 

5.6           Laws.
Borrower is not in violation of any law, rule or regulation, or in default with respect to any judgment, writ, injunction or decree
of any governmental authority, where such violation or default is reasonably expected to result in a Material Adverse Effect.
Borrower is not in default in any manner under any provision of any agreement or instrument evidencing indebtedness, or any other
material agreement to which it is a party or by which it is bound.

 

5.7           Information
Correct and Current. No information, report, Advance Request, financial statement, exhibit or schedule furnished, by or on behalf
of Borrower to Lender in connection with any Loan Document or included therein or delivered pursuant thereto contained or contains
any material misstatement of fact or omitted, omits or will omit to state any material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading at the time such statement was made or deemed made.
Additionally, any and all financial or business projections provided by Borrower to Lender shall be (i) provided in good faith
and based on the most current data and information available to Borrower, and (ii) the most current of such projections provided
to Borrower’s Board of Directors.

 

5.8           Tax
Matters. Except as described on Schedule 5.8, (a) Borrower has filed all federal, state and local tax returns that it is required
to file, (b) Borrower has duly paid or fully reserved for all taxes or installments thereof (including any interest or penalties)
as and when due, which have or may become due pursuant to such returns, and (c) Borrower has paid or fully reserved for any tax
assessment received by Borrower for the three (3) years preceding the Closing Date, if any (including any taxes being contested
in good faith and by appropriate proceedings).

 

    	17

    	 

    

 

5.9           Intellectual
Property Claims. Except as described on Schedule 5.9, Borrower is the sole owner of, or otherwise has the right to use, the Intellectual
Property. Except as described on Schedule 5.9, (i) each of the material Copyrights, Trademarks and Patents is valid and enforceable,
(ii) no material part of the Intellectual Property has been judged invalid or unenforceable, in whole or in part, and (iii) no
claim has been made to Borrower that any material part of the Intellectual Property violates the rights of any third party. Exhibit D
is a true, correct and complete list of each of Borrower’s Patents, registered Trademarks, registered Copyrights, and material
agreements under which Borrower licenses Intellectual Property from third parties (other than shrink-wrap software licenses),
together with application or registration numbers, as applicable, owned by Borrower or any Subsidiary, in each case as of the
Closing Date. Borrower is not in material breach of, nor has Borrower failed to perform any material obligations under, any of
the foregoing contracts, licenses or agreements and, to Borrower’s knowledge, no third party to any such contract, license
or agreement is in material breach thereof or has failed to perform any material obligations thereunder.

 

5.10         Intellectual
Property. Except as described on Schedule 5.10, Borrower has, or in the case of any proposed business, will have, all material
rights with respect to Intellectual Property necessary in the operation or conduct of Borrower’s business as currently conducted
by Borrower. Without limiting the generality of the foregoing, and in the case of Licenses, except for restrictions that are unenforceable
under Division 9 of the UCC, Borrower has the right, to the extent required to operate Borrower’s business, to freely transfer,
license or assign Intellectual Property without condition, restriction or payment of any kind (other than license payments in
the ordinary course of business) to any third party, and Borrower owns or has the right to use, pursuant to valid licenses, all
software development tools, library functions, compilers and all other third-party software and other items that are used in the
design, development, promotion, sale, license, manufacture, import, export, use or distribution of Borrower Products.

 

5.11         Borrower
Products and Intellectual Property. Except as described on Schedule 5.11, no Intellectual Property owned by Borrower or Borrower
Product has been or is subject to any actual or, to the knowledge of Borrower, threatened litigation, proceeding (including any
proceeding in the United States Patent and Trademark Office or any corresponding foreign office or agency) or outstanding decree,
order, judgment, settlement agreement or stipulation that restricts in any manner Borrower’s use, transfer or licensing
thereof or that may affect the validity, use or enforceability thereof. There is no decree, order, judgment, agreement, stipulation,
arbitral award or other provision entered into in connection with any litigation or proceeding that obligates Borrower to grant
licenses or ownership interest in any future Intellectual Property related to the operation or conduct of the business of Borrower
or Borrower Products. Borrower has not received any written notice or claim, or, to the knowledge of Borrower, oral notice or
claim, challenging or questioning Borrower’s ownership in any Intellectual Property (or written notice of any claim challenging
or questioning the ownership in any licensed Intellectual Property of the owner thereof) or suggesting that any third party has
any claim of legal or beneficial ownership with respect thereto nor, to Borrower’s knowledge, is there a reasonable basis
for any such claim. Neither Borrower’s use of its Intellectual Property nor the production and sale of Borrower Products
infringes the Intellectual Property or other rights of others.

 

    	18

    	 

    

 

5.12         Financial
Accounts. Exhibit E, as may be updated by the Borrower in a written notice provided to Lender after the Closing Date, is a true,
correct and complete list of (a) all banks and other financial institutions at which Borrower or any Subsidiary maintains
Deposit Accounts and (b) all institutions at which Borrower or any Subsidiary maintains an account holding Investment Property,
and such exhibit correctly identifies the name, address and telephone number of each bank or other institution, the name in which
the account is held, a description of the purpose of the account, and the complete account number therefor.

 

5.13         Employee
Loans. Borrower has no outstanding loans to any employee, officer or director of the Borrower nor has Borrower guaranteed the
payment of any loan made to an employee, officer or director of the Borrower by a third party.

 

5.14         Capitalization
and Subsidiaries. Borrower’s capitalization as of the Closing Date is set forth on Schedule 5.14 annexed hereto. Borrower
does not own any stock, partnership interest or other securities of any Person, except for Permitted Investments. Attached as
Schedule 5.14, as may be updated by Borrower in a written notice provided after the Closing Date, is a true, correct and complete
list of each Subsidiary.

 

SECTION
6. INSURANCE; INDEMNIFICATION

 

6.1           Coverage.
Borrower shall cause to be carried and maintained commercial general liability insurance, on an occurrence form, against risks
customarily insured against in Borrower’s line of business. Such risks shall include the risks of bodily injury, including
death, property damage, personal injury, advertising injury, and contractual liability per the terms of the indemnification agreement
found in Section 6.3. Borrower must maintain a minimum of $1,000,000 of commercial general liability insurance for each occurrence.
Borrower has and agrees to maintain directors and officers’ insurance of not less than $5,000,000 in the aggregate. So long
as there are any Secured Obligations outstanding, Borrower shall also cause to be carried and maintained insurance upon the Collateral,
insuring against all risks of physical loss or damage howsoever caused, in an amount not less than the full replacement cost of
the Collateral, provided that such insurance may be subject to standard exceptions and deductibles.

 

6.2           Certificates.
Borrower shall deliver to Lender certificates of insurance that evidence Borrower’s compliance with its insurance obligations
in Section 6.1 and the obligations contained in this Section 6.2. Borrower’s insurance certificate shall state
Lender is an additional insured for commercial general liability, a loss payee for all risk property damage insurance, subject
to the insurer’s approval, and a loss payee for property insurance and additional insured for liability insurance for any
future insurance that Borrower may acquire from such insurer. Attached to the certificates of insurance will be additional insured
endorsements for liability and lender’s loss payable endorsements for all risk property damage insurance. All certificates
of insurance will provide for a minimum of thirty (30) days advance written notice to Lender of cancellation or any other change
adverse to Lender’s interests. Any failure of Lender to scrutinize such insurance certificates for compliance is not a waiver
of any of Lender’s rights, all of which are reserved.

 

    	19

    	 

    

  

6.3           Indemnity.
Borrower agrees to indemnify and hold Lender and its officers, directors, employees, agents, in-house attorneys, representatives
and shareholders harmless from and against any and all claims, costs, expenses, damages and liabilities (including such claims,
costs, expenses, damages and liabilities based on liability in tort, including strict liability in tort), including reasonable
attorneys’ fees and disbursements and other costs of investigation or defense (including those incurred upon any appeal),
that may be instituted or asserted against or incurred by Lender or any such Person as the result of credit having been extended,
suspended or terminated under this Agreement and the other Loan Documents, excluding the Warrant, or the administration of such
credit, or in connection with or arising out of the transactions contemplated hereunder and thereunder, or any actions or failures
to act in connection therewith, or arising out of the disposition or utilization of the Collateral, excluding in all cases claims
resulting from Lender’s gross negligence or willful misconduct. Borrower agrees to pay, and to save Lender harmless from,
any and all liabilities with respect to, or resulting from any delay in paying, any and all excise, sales or other similar taxes
(excluding taxes imposed on or measured by the net income of Lender) that may be payable or determined to be payable with respect
to any of the Collateral or this Agreement.

 

SECTION
7. COVENANTS

 

Borrower agrees
as follows:

 

7.1           Financial
Reports. For so long as any of the Secured Obligations are outstanding, Borrower shall furnish to Lender the financial statements
and reports listed hereinafter (the “Financial Statements”):

 

(a)          as
soon as practicable (and in any event within 30 days) after the end of each month, unaudited interim and year-to-date financial
statements as of the end of such month (prepared on a consolidated and consolidating basis, if applicable), including balance
sheet and related statements of income and cash flows accompanied by a report detailing any material contingencies (including
the commencement of any material litigation by or against Borrower) or any other occurrence that would reasonably be expected
to have a Material Adverse Effect, all certified by Borrower’s Chief Executive Officer or Chief Financial Officer to the
effect that they have been prepared in accordance with GAAP, except (i) for the absence of footnotes, (ii) that they are subject
to normal year end adjustments, and (iii) they do not contain certain non-cash items that are customarily included in quarterly
and annual financial statements;

 

(b)          as
soon as practicable (and in any event within 50 days), concurrently with SEC filings made after the end of each calendar quarter,
unaudited interim and year-to-date financial statements as of the end of such calendar quarter (prepared on a consolidated and
consolidating basis, if applicable), including balance sheet and related statements of income and cash flows accompanied by a
report detailing any material contingencies (including the commencement of any material litigation by or against Borrower) or
any other occurrence that would reasonably be expected to have a Material Adverse Effect, certified by Borrower’s Chief
Executive Officer or Chief Financial Officer to the effect that they have been prepared in accordance with GAAP, except (i) for
the absence of footnotes, and (ii) that they are subject to normal year end adjustments; as well as the most recent capitalization
table for Borrower, including the weighted average exercise price of employee stock options, provided, however, that such documents
will be deemed to be delivered on the date that the SEC makes such documents publicly available, Borrower advises Lender of the
same and provides a link to such documents;

 

    	20

    	 

    

  

(c)          as
soon as practicable (and in any event within one hundred fifty (150) days) after the end of each fiscal year, unqualified (except
as may be qualified by a going concern qualification made solely because of the incorporation of Section 9.3 into this Agreement)
audited financial statements as of the end of such year (prepared on a consolidated and consolidating basis, if applicable), including
balance sheet and related statements of income and cash flows, and setting forth in comparative form the corresponding figures
for the preceding fiscal year, certified by a firm of independent certified public accountants selected by Borrower and reasonably
acceptable to Lender, which Lender confirms that Stegman & Company is reasonably acceptable, accompanied by any management
report from such accountants, provided, however, that such documents will be deemed to be delivered on the date that the SEC makes
such documents publicly available, Borrower advises Lender of the same and provides a link to such documents;

 

(d)          as
soon as practicable (and in any event within 30 days) after the end of each month, a Compliance Certificate in the form of Exhibit
F;

 

(e)          as
part of the report to be provided pursuant to Section 7.1 (a) the Borrower will provide agings of accounts receivable and accounts
payable;

 

(f)          promptly
after the sending or filing thereof, as the case may be, copies of any proxy statements, financial statements or reports that
Borrower has made available to holders of its Preferred Stock and copies of any regular, periodic and special reports or registration
statements that Borrower files with the Securities and Exchange Commission or any governmental authority that may be substituted
therefor, or any national securities exchange, however, any such documents will be deemed to be delivered on the date that the
SEC makes such documents publicly available, Borrower advises Lender of the same and provides a link to such documents;

 

and

 

(g)          financial
and business projections promptly following their approval by Borrower’s Board of Directors, as well as budgets, operating
plans and other financial information reasonably requested by Lender.

 

Borrower
shall not make any change in its (a) accounting policies or reporting practices, except as required by GAAP or (b) fiscal years
or fiscal quarters without the prior written consent of Lender which shall not be unreasonably withheld. The fiscal year of Borrower
shall end on December 31.

 

    	21

    	 

    

 

 

The
executed Compliance Certificate may be sent via facsimile to Lender at (650) 473-9194 or via e-mail to cnorman@herculestech.com.
All Financial Statements required to be delivered pursuant to clauses (a), (b) and (c) shall be sent via e-mail to financialstatements@herculestech.com
with a copy to cnnorman@herculestech.com provided, that if e-mail is not available or sending such Financial Statements
via e-mail is not possible, they shall be sent via facsimile to Lender at: (866) 468-8916, attention Chief Credit Officer.

 

7.2           Management
Rights. Borrower shall permit any representative that Lender authorizes, including its attorneys and accountants, to inspect the
Collateral and examine and make copies and abstracts of the books of account and records of Borrower at reasonable times and upon
reasonable notice during normal business hours. In addition, any such representative shall have the right to meet with management
and officers of Borrower to discuss such books of account and records. In addition, Lender shall be entitled at reasonable times
and intervals to consult with and advise the management and officers of Borrower concerning significant business issues affecting
Borrower. Such consultations shall not unreasonably interfere with Borrower’s business operations. The parties intend that
the rights granted Lender shall constitute “management rights” within the meaning of 29 C.F.R Section 2510.3-101(d)(3)(ii),
but that any advice, recommendations or participation by Lender with respect to any business issues shall not be deemed to give
Lender, nor be deemed an exercise by Lender of, control over Borrower’s management or policies.

 

7.3           Further
Assurances. Borrower shall from time to time execute, deliver and file, alone or with Lender, any financing statements, security
agreements, collateral assignments, notices, control agreements, or other documents to perfect or give the highest priority to
Lender’s Lien on the Collateral. Borrower shall from time to time procure any instruments or documents as may be requested
by Lender, and take all further action that may be necessary or desirable, or that Lender may reasonably request, to perfect and
protect the Liens granted hereby and thereby. In addition, and for such purposes only, Borrower hereby authorizes Lender to execute
and deliver on behalf of Borrower and to file such financing statements, collateral assignments, notices, control agreements,
security agreements and other documents without the signature of Borrower either in Lender’s name or in the name of Lender
as agent and attorney-in-fact for Borrower. Borrower shall protect and defend Borrower’s title to the Collateral and Lender’s
Lien thereon against all Persons claiming any interest adverse to Borrower or Lender other than Permitted Liens.

 

7.4           Indebtedness.
Borrower shall not create, incur, assume, guarantee or be or remain liable with respect to any Indebtedness, or permit any Subsidiary
so to do, other than Permitted Indebtedness, or prepay any Indebtedness or take any actions which impose on Borrower an obligation
to prepay any Indebtedness, except for the conversion of Indebtedness into equity securities and the payment of cash in lieu of
fractional shares in connection with such conversion.

 

    	22

    	 

    

 

7.5           Collateral.
Borrower shall at all times keep the Collateral and all other property and assets used in Borrower’s business or in which
Borrower now or hereafter holds any interest free and clear from any legal process or Liens whatsoever (except for Permitted Liens),
and shall give Lender prompt written notice of any legal process affecting the Collateral, such other property and assets, or
any Liens thereon. Borrower shall cause its Subsidiaries to protect and defend such Subsidiary’s title to its assets from
and against all Persons claiming any interest adverse to such Subsidiary, and Borrower shall cause its Subsidiaries at all times
to keep such Subsidiary’s property and assets free and clear from any legal process or Liens whatsoever (except for Permitted
Liens), and shall give Lender prompt written notice of any legal process affecting such Subsidiary’s assets.

 

7.6           Investments.
Borrower shall not directly or indirectly acquire or own, or make any Investment in or to any Person, or permit any of its Subsidiaries
so to do, other than Permitted Investments.

 

7.7           Distributions.
Borrower shall not, and shall not allow any Subsidiary to, (a) repurchase or redeem any class of stock or other equity interest
other than pursuant to employee, director or consultant repurchase plans or other similar agreements, provided, however, in each
case the repurchase or redemption price does not exceed the original consideration paid for such stock or equity interest, or
(b) declare or pay any cash dividend or make a cash distribution on any class of stock or other equity interest, except that a
Subsidiary may pay dividends or make distributions to Borrower, or (c) lend money to any employees, officers or directors or guarantee
the payment of any such loans granted by a third party in excess of $100,000 in the aggregate or (d) waive, release or forgive
any indebtedness owed by any employees, officers or directors in excess of $100,000 in the aggregate.

 

7.8           Transfers.
Except for Permitted Transfers, Borrower shall not voluntarily or involuntarily transfer, sell, lease, license, lend or in any
other manner convey any equitable, beneficial or legal interest in any material portion of its assets.

 

7.9           Mergers
or Acquisitions. Borrower shall not merge or consolidate, or permit any of its Subsidiaries to merge or consolidate, with or into
any other business organization (other than mergers or consolidations of a Subsidiary into another Subsidiary or into Borrower),
or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another
Person.

 

7.10         Taxes.
Borrower and its Subsidiaries shall pay when due all taxes, fees or other charges of any nature whatsoever (together with any
related interest or penalties) now or hereafter imposed or assessed against Borrower, Lender or the Collateral or upon Borrower’s
ownership, possession, use, operation or disposition thereof or upon Borrower’s rents, receipts or earnings arising therefrom.
Borrower shall file on or before the due date therefor all personal property tax returns in respect of the Collateral. Notwithstanding
the foregoing, Borrower may contest, in good faith and by appropriate proceedings, taxes for which Borrower maintains adequate
reserves therefor in accordance with GAAP.

 

    	23

    	 

    

 

7.11         Corporate
Changes. Neither Borrower nor any Subsidiary shall change its corporate name, legal form or jurisdiction of formation without
twenty (20) days’ prior written notice to Lender. Neither Borrower nor any Subsidiary shall relocate its chief executive
office or its principal place of business unless: (i) it has provided prior written notice to Lender; and (ii) such relocation
shall be within the continental United States. Neither Borrower nor any Subsidiary shall relocate any item of Collateral (other
than (x) sales of Inventory in the ordinary course of business, (y) relocations of Equipment having an aggregate value of up to
$150,000 in any fiscal year, and (z) relocations of Collateral from a location described on Exhibit C to another location described
on Exhibit C) unless (i) it has provided prompt written notice to Lender, (ii) such relocation is within the continental United
States and, (iii) if such relocation is to a third party bailee, it has delivered a bailee agreement in form and substance reasonably
acceptable to Lender.

 

7.12         Deposit
Accounts. Neither Borrower nor any Subsidiary shall maintain any Deposit Accounts, or accounts holding Investment Property, except
with respect to which Lender has an Account Control Agreement; notwithstanding the above, no Account Control Agreement shall be
required in connection with Borrower’s Deposit Account held with Bank of America as shown on Exhibit E so long as such Deposit
Account is closed by April 22, 2013.

 

7.13         Borrower
shall notify Lender of each Subsidiary formed subsequent to the Closing Date and, within 15 days of formation, shall cause any
such Subsidiary organized under the laws of any State within the United States to execute and deliver to Lender a Joinder Agreement.

 

7.14         Lender
has received a license from the U.S. Small Business Administration (“SBA”) to extend loans as a small business investment
company (“SBIC”) pursuant to the Small Business Investment Act of 1958, as amended, and the associated regulations
(collectively, the “SBIC Act”). Portions of the loan to Borrower will be made under the SBA license and the SBIC Act.
Addendum 1 to this Agreement outlines various responsibilities of Lender and Borrower associated with an SBA loan, and such Addendum
1 is hereby incorporated in this Agreement.

 

7.15         Lender
is an “accredited investor,” as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933,
as amended by the Dodd-Frank Wall Street Reform and Consumer Protection Act.

 

7.16         Lender
is making the Loans referred to herein and any subsequent conversions of the Loan into Common Stock of the Borrower as an investment
for its own account and not with a view to resell or distribute any securities of the Borrower; provided, however, that nothing
in this Section 7.16 shall in any way be deemed an agreement to limit or otherwise restrict Lender’s right to sell or transfer
any securities of the Borrower except as stated explicitly in this Agreement. 

 

    	24

    	 

    

 

 

SECTION
8. RIGHT TO invest;RIGHT TO CONVERT 

 

8.1           Lender
or its assignee or nominee shall have the right, in its discretion, to participate in any Subsequent Financing in an amount of
up to $1,000,000 on the same terms, conditions and pricing afforded to others participating in any such Subsequent Financing.

 

SECTION
9. EVENTS OF DEFAULT

 

The occurrence
of any one or more of the following events shall be an Event of Default:

 

9.1           Payments.
Borrower fails to pay any amount due under this Agreement or any of the other Loan Documents on the due date; or

 

9.2           Covenants.
Borrower breaches or defaults in the performance of any covenant or Secured Obligation under this Agreement, or any of the other
Loan Documents, and (a) with respect to a default under any covenant under this Agreement (other than under Sections 6, 7.4,
7.5, 7.6, 7.7, 7.8, 7.9 and 7.14) such default continues for more than fifteen (15) days after the earlier of the date on which
(i) Lender has given notice of such default to Borrower and (ii) Borrower has actual knowledge of such default or (b) with respect
to a default under any of Sections 6, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9 or 7.14, the occurrence of such default; or

 

9.3           Material
Adverse Effect. A circumstance constituting a Material Adverse Effect; or

 

9.4           Other
Loan Documents. The occurrence of any default under any Loan Document or any other agreement between Borrower and Lender and such
default continues for more than fifteen (15) days after the earlier of (a) Lender has given notice of such default to Borrower,
or (b) Borrower has actual knowledge of such default; or

 

9.5           Representations.
Any representation or warranty made by Borrower in any Loan Document or in the Warrant shall have been false or misleading in
any material respect; or

 

9.6           Insolvency.
Borrower (A) (i) shall make an assignment for the benefit of creditors; or (ii) shall be unable to pay its debts as
they become due, or be unable to pay or perform under the Loan Documents, or shall become insolvent; or (iii) shall file
a voluntary petition in bankruptcy; or (iv) shall file any petition, answer, or document seeking for itself any reorganization,
arrangement, composition, readjustment, liquidation, dissolution or similar relief under any present or future statute, law or
regulation pertinent to such circumstances; or (v) shall seek or consent to or acquiesce in the appointment of any trustee,
receiver, or liquidator of Borrower or of all or any substantial part (i.e., 33-1/3% or more) of the assets or property of Borrower;
or (vi) shall cease operations of its business as its business has normally been conducted, or terminate substantially all
of its employees; or (vii) Borrower or its directors or majority shareholders shall take any action initiating any of the
foregoing actions described in clauses (i) through (vi); or (B) either (i) forty five (45) days shall have expired after
the commencement of an involuntary action against Borrower seeking reorganization, arrangement, composition, readjustment, liquidation,
dissolution or similar relief under any present or future statute, law or regulation, without such action being dismissed or all
orders or proceedings thereunder affecting the operations or the business of Borrower being stayed; or (ii) a stay of any
such order or proceedings shall thereafter be set aside and the action setting it aside shall not be timely appealed; or (iii) Borrower
shall file any answer admitting or not contesting the material allegations of a petition filed against Borrower in any such proceedings;
or (iv) the court in which such proceedings are pending shall enter a decree or order granting the relief sought in any such
proceedings; or (v) forty five (45) days shall have expired after the appointment, without the consent or acquiescence of Borrower,
of any trustee, receiver or liquidator of Borrower or of all or any substantial part of the properties of Borrower without such
appointment being vacated; or

 

    	25

    	 

    

  

9.7           Attachments;
Judgments. Any portion of Borrower’s assets is attached or seized, or a levy is filed against any such assets, or a judgment
or judgments is/are entered for the payment of money, individually or in the aggregate, of at least $250,000 and shall remain
unsatisfied, unvacated or unstayed for a period of twenty (20) days, or Borrower is enjoined or in any way prevented by court
order from conducting any part of its business; or

 

9.8           Other
Obligations. Other than bona fide disputes in the order course of business, the occurrence of any default under any agreement
or obligation of Borrower involving any Indebtedness in a principle amount in excess of $250,000, or the occurrence of any default
under any agreement or obligation of Borrower that could reasonably be expected to have a Material Adverse Effect.

 

SECTION
10. REMEDIES

 

10.1         General.
Upon and during the continuance of any one or more Events of Default, (i) Lender may, at its option, accelerate and demand payment
of all or any part of the Secured Obligations together with a Prepayment Charge and declare them to be immediately due and payable
(provided, that upon the occurrence of an Event of Default of the type described in Section 9.6, all of the Secured Obligations
shall automatically be accelerated and made due and payable, in each case without any further notice or act), and (ii) Lender
may notify any of Borrower’s account debtors to make payment directly to Lender, compromise the amount of any such account
on Borrower’s behalf and endorse Lender’s name without recourse on any such payment for deposit directly to Lender’s
account. Lender may exercise all rights and remedies with respect to the Collateral under the Loan Documents or otherwise available
to it under the UCC and other applicable law, including the right to release, hold, sell, lease, liquidate, collect, realize upon,
or otherwise dispose of all or any part of the Collateral and the right to occupy, utilize, process and commingle the Collateral.
All Lender’s rights and remedies shall be cumulative and not exclusive.

 

10.2         Collection;
Foreclosure. Upon the occurrence and during the continuance of any Event of Default, Lender may, at any time or from time to time,
apply, collect, liquidate, sell in one or more sales, lease or otherwise dispose of, any or all of the Collateral, in its then
condition or following any commercially reasonable preparation or processing, in such order as Lender may elect. Any such sale
may be made either at public or private sale at its place of business or elsewhere. Borrower agrees that any such public or private
sale may occur upon ten (10) calendar days’ prior written notice to Borrower. Lender may require Borrower to assemble the
Collateral and make it available to Lender at a place designated by Lender that is reasonably convenient to Lender and Borrower.
The proceeds of any sale, disposition or other realization upon all or any part of the Collateral shall be applied by Lender in
the following order of priorities:

 

    	26

    	 

    

  

First,
to Lender in an amount sufficient to pay in full Lender’s costs and professionals’ and advisors’ fees and expenses
as described in Section 11.11;

 

Second,
to Lender in an amount equal to the then unpaid amount of the Secured Obligations (including principal, interest, and the Default
Rate interest), in such order and priority as Lender may choose in its sole discretion; and

 

Finally,
after the full, final, and indefeasible payment in Cash of all of the Secured Obligations, to any creditor holding a junior Lien
on the Collateral, or to Borrower or its representatives or as a court of competent jurisdiction may direct.

 

Lender shall be deemed to have acted
reasonably in the custody, preservation and disposition of any of the Collateral if it complies with the obligations of a secured
party under the UCC.

 

10.3         No
Waiver. Lender shall be under no obligation to marshal any of the Collateral for the benefit of Borrower or any other Person,
and Borrower expressly waives all rights, if any, to require Lender to marshal any Collateral.

 

10.4         Cumulative
Remedies. The rights, powers and remedies of Lender hereunder shall be in addition to all rights, powers and remedies given by
statute or rule of law and are cumulative. The exercise of any one or more of the rights, powers and remedies provided herein
shall not be construed as a waiver of or election of remedies with respect to any other rights, powers and remedies of Lender.

 

SECTION
11. MISCELLANEOUS

 

11.1         Severability.
Whenever possible, each provision of this Agreement shall be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement shall be prohibited by or invalid under such law, such provision shall be ineffective
only to the extent and duration of such prohibition or invalidity, without invalidating the remainder of such provision or the
remaining provisions of this Agreement.

 

11.2         Notice.
Except as otherwise provided herein, any notice, demand, request, consent, approval, declaration, service of process or other
communication (including the delivery of Financial Statements) that is required, contemplated, or permitted under the Loan Documents
or with respect to the subject matter hereof shall be in writing, and shall be deemed to have been validly served, given, delivered,
and received upon the earlier of: (i) the day of transmission by facsimile or hand delivery or delivery by an overnight express
service or overnight mail delivery service; or (ii) the third calendar day after deposit in the United States mails, with
proper first class postage prepaid, in each case addressed to the party to be notified as follows:

 

    	27

    	 

    

  

		(a)	If to Lender:

 

HERCULES TECHNOLOGY III,
L.P.

Legal Department

Attention: Chief Legal Officer and Chad Norman

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Facsimile: 650-473-9194

Telephone: 650-289-3060

 

		(b)	If to Borrower:

 

NEURALSTEM, INC.

 

Attention: Richard Garr,
Chief Executive Officer

9700 Great Seneca Parkway

Rockville, MD 20850

Facsimile: 301-560-6634

Telephone: 240-475-3148

 

or to such other
address as each party may designate for itself by like notice.

 

11.3         Entire
Agreement; Amendments. This Agreement and the other Loan Documents constitute the entire agreement and understanding of the parties
hereto in respect of the subject matter hereof and thereof, and supersede and replace in their entirety any prior proposals, term
sheets, non-disclosure or confidentiality agreements, letters, negotiations or other documents or agreements, whether written
or oral, with respect to the subject matter hereof or thereof (including Lender’s revised proposal letter dated February
22, 2013). None of the terms of this Agreement or any of the other Loan Documents may be amended except by an instrument executed
by each of the parties hereto.

 

11.4         No
Strict Construction. The parties hereto have participated jointly in the negotiation and drafting of this Agreement. In the event
an ambiguity or question of intent or interpretation arises, this Agreement shall be construed as if drafted jointly by the parties
hereto and no presumption or burden of proof shall arise favoring or disfavoring any party by virtue of the authorship of any
provisions of this Agreement.

 

11.5         No
Waiver. The powers conferred upon Lender by this Agreement are solely to protect its rights hereunder and under the other Loan
Documents and its interest in the Collateral and shall not impose any duty upon Lender to exercise any such powers. No omission
or delay by Lender at any time to enforce any right or remedy reserved to it, or to require performance of any of the terms, covenants
or provisions hereof by Borrower at any time designated, shall be a waiver of any such right or remedy to which Lender is entitled,
nor shall it in any way affect the right of Lender to enforce such provisions thereafter.

 

11.6         Survival.
All agreements, representations and warranties contained in this Agreement and the other Loan Documents or in any document delivered
pursuant hereto or thereto shall be for the benefit of Lender and shall survive the execution and delivery of this Agreement and
the expiration or other termination of this Agreement.

 

    	28

    	 

    

  

11.7         Successors
and Assigns. The provisions of this Agreement and the other Loan Documents shall inure to the benefit of and be binding on Borrower
and its permitted assigns (if any). Borrower shall not assign its obligations under this Agreement or any of the other Loan Documents
without Lender’s express prior written consent, and any such attempted assignment shall be void and of no effect. Lender
may assign, transfer, or endorse its rights hereunder and under the other Loan Documents without prior notice to Borrower, and
all of such rights shall inure to the benefit of Lender’s successors and assigns, provided that prior to the occurrence
of an Event of Default, Lender shall not assign its rights hereunder and under the other Loan Documents to any Person involved
in the development and commercialization of drugs or treatments in the pharmaceutical or biotechnology industries unless such
assignment is pre-approved in writing by Borrower, and any such attempt to assign without such consent prior to the occurrence
of an Event of Default shall be void and of no effect.

 

11.8         Governing
Law. This Agreement and the other Loan Documents have been negotiated and delivered to Lender in the State of California, and
shall have been accepted by Lender in the State of California. Payment to Lender by Borrower of the Secured Obligations is due
in the State of California. This Agreement and the other Loan Documents shall be governed by, and construed and enforced in accordance
with, the laws of the State of California, excluding conflict of laws principles that would cause the application of laws of any
other jurisdiction.

 

11.9         Consent
to Jurisdiction and Venue. All judicial proceedings (to the extent that the reference requirement of Section 11.10 is not applicable)
arising in or under or related to this Agreement or any of the other Loan Documents may be brought in any state or federal court
located in the State of California. By execution and delivery of this Agreement, each party hereto generally and unconditionally:
(a) consents to nonexclusive personal jurisdiction in Santa Clara County, State of California; (b) waives any objection
as to jurisdiction or venue in Santa Clara County, State of California; (c) agrees not to assert any defense based on lack
of jurisdiction or venue in the aforesaid courts; and (d) irrevocably agrees to be bound by any judgment rendered thereby
in connection with this Agreement or the other Loan Documents. Service of process on any party hereto in any action arising out
of or relating to this Agreement shall be effective if given in accordance with the requirements for notice set forth in Section 11.2,
and shall be deemed effective and received as set forth in Section 11.2. Nothing herein shall affect the right to serve process
in any other manner permitted by law or shall limit the right of either party to bring proceedings in the courts of any other
jurisdiction.

 

11.10         Mutual
Waiver of Jury Trial / Judicial Reference.

 

    	29

    	 

    

 

(a)          Because
disputes arising in connection with complex financial transactions are most quickly and economically resolved by an experienced
and expert person and the parties wish applicable state and federal laws to apply (rather than arbitration rules), the parties
desire that their disputes be resolved by a judge applying such applicable laws. EACH OF BORROWER AND LENDER SPECIFICALLY WAIVES
ANY RIGHT IT MAY HAVE TO TRIAL BY JURY OF ANY CAUSE OF ACTION, CLAIM, CROSS-CLAIM, COUNTERCLAIM, THIRD PARTY CLAIM OR ANY OTHER
CLAIM (COLLECTIVELY, “CLAIMS”) ASSERTED BY BORROWER AGAINST LENDER OR ITS ASSIGNEE OR BY LENDER OR ITS ASSIGNEE AGAINST
BORROWER. This waiver extends to all such Claims, including Claims that involve Persons other than Borrower and Lender; Claims
that arise out of or are in any way connected to the relationship between Borrower and Lender; and any Claims for damages, breach
of contract, tort, specific performance, or any equitable or legal relief of any kind, arising out of this Agreement, any other
Loan Document.

 

(b)          If
the waiver of jury trial set forth in Section 11.10(a) is ineffective or unenforceable, the parties agree that all Claims shall
be resolved by reference to a private judge sitting without a jury, pursuant to Code of Civil Procedure Section 638, before a
mutually acceptable referee or, if the parties cannot agree, a referee selected by the Presiding Judge of the Santa Clara County,
California. Such proceeding shall be conducted in Santa Clara County, California, with California rules of evidence and discovery
applicable to such proceeding.

 

(c)          In
the event Claims are to be resolved by judicial reference, either party may seek from a court identified in Section 11.9, any
prejudgment order, writ or other relief and have such prejudgment order, writ or other relief enforced to the fullest extent permitted
by law notwithstanding that all Claims are otherwise subject to resolution by judicial reference.

 

11.11         Professional
Fees. Borrower promises to pay Lender’s fees and expenses necessary to finalize the loan documentation, including but not
limited to reasonable attorneys fees, UCC searches, filing costs, and other miscellaneous expenses. In addition, Borrower promises
to pay any and all reasonable attorneys’ and other professionals’ fees and expenses (including fees and expenses of
in-house counsel) incurred by Lender after the Closing Date in connection with or related to: (a) the Loan; (b) the
administration, collection, or enforcement of the Loan; (c) the amendment or modification of the Loan Documents; (d) any
waiver, consent, release, or termination under the Loan Documents; (e) the protection, preservation, sale, lease, liquidation,
or disposition of Collateral or the exercise of remedies with respect to the Collateral; (f) any legal, litigation, administrative,
arbitration, or out of court proceeding in connection with or related to Borrower or the Collateral, and any appeal or review
thereof; and (g) any bankruptcy, restructuring, reorganization, assignment for the benefit of creditors, workout, foreclosure,
or other action related to Borrower, the Collateral, the Loan Documents, including representing Lender in any adversary proceeding
or contested matter commenced or continued by or on behalf of Borrower’s estate, and any appeal or review thereof.

 

    	30

    	 

    

 

11.12         Confidentiality.
Lender acknowledges that certain items of Collateral and information provided to Lender by Borrower are confidential and proprietary
information of Borrower, if and to the extent such information either (x) is marked as confidential by Borrower at the time of
disclosure, or (y) should reasonably be understood to be confidential (the “Confidential Information”). Accordingly,
Lender agrees that any Confidential Information it may obtain in the course of acquiring, administering, or perfecting Lender’s
security interest in the Collateral shall not be disclosed to any other person or entity in any manner whatsoever, in whole or
in part, without the prior written consent of Borrower, except that Lender may disclose any such information: (a) to its own
directors, officers, employees, accountants, counsel and other professional advisors and to its affiliates if Lender in its sole
discretion determines that any such party should have access to such information in connection with such party’s responsibilities
in connection with the Loan or this Agreement and, provided that such recipient of such Confidential Information either (i) agrees
to be bound by the confidentiality provisions of this paragraph or (ii) is otherwise subject to confidentiality restrictions that
reasonably protect against the disclosure of Confidential Information; (b) if such information is generally available to the
public; (c) if required or appropriate in any report, statement or testimony submitted to any governmental authority having
or claiming to have jurisdiction over Lender; (d) if required or appropriate in response to any summons or subpoena or in
connection with any litigation, to the extent permitted or deemed advisable by Lender’s counsel; (e) to comply with
any legal requirement or law applicable to Lender; (f) to the extent reasonably necessary in connection with the exercise
of any right or remedy under any Loan Document, including Lender’s sale, lease, or other disposition of Collateral after
default; (g) to any participant or assignee of Lender or any prospective participant or assignee; provided, that such participant
or assignee or prospective participant or assignee agrees in writing to be bound by this Section prior to disclosure; or (h) otherwise
with the prior consent of Borrower; provided, that any disclosure made in violation of this Agreement shall not affect the obligations
of Borrower or any of its affiliates or any guarantor under this Agreement or the other Loan Documents.

 

11.13         Assignment
of Rights. Borrower acknowledges and understands that Lender may sell and assign all or part of its interest hereunder and under
the Loan Documents to any person or entity (an “Assignee”), subject to any restrictions included in Section 11.7. After
such assignment the term “Lender” as used in the Loan Documents shall mean and include such Assignee, and such Assignee
shall be vested with all rights, powers and remedies of Lender hereunder with respect to the interest so assigned; but with respect
to any such interest not so transferred, Lender shall retain all rights, powers and remedies hereby given. No such assignment by
Lender shall relieve Borrower of any of its obligations hereunder. Lender agrees that in the event of any transfer by it of the
Note(s)(if any), it will endorse thereon a notation as to the portion of the principal of the Note(s), which shall have been paid
at the time of such transfer and as to the date to which interest shall have been last paid thereon.

 

11.14         Revival
of Secured Obligations. This Agreement and the Loan Documents shall remain in full force and effect and continue to be effective
if any petition is filed by or against Borrower for liquidation or reorganization, if Borrower becomes insolvent or makes an assignment
for the benefit of creditors, if a receiver or trustee is appointed for all or any significant part of Borrower’s assets,
or if any payment or transfer of Collateral is recovered from Lender. The Loan Documents and the Secured Obligations and Collateral
security shall continue to be effective, or shall be revived or reinstated, as the case may be, if at any time payment and performance
of the Secured Obligations or any transfer of Collateral to Lender, or any part thereof is rescinded, avoided or avoidable, reduced
in amount, or must otherwise be restored or returned by, or is recovered from, Lender or by any obligee of the Secured Obligations,
whether as a “voidable preference,” “fraudulent conveyance,” or otherwise, all as though such payment,
performance, or transfer of Collateral had not been made. In the event that any payment, or any part thereof, is rescinded, reduced,
avoided, avoidable, restored, returned, or recovered, the Loan Documents and the Secured Obligations shall be deemed, without any
further action or documentation, to have been revived and reinstated except to the extent of the full, final, and indefeasible
payment to Lender in Cash.

 

    	31

    	 

    

 

11.15         Counterparts.
This Agreement and any amendments, waivers, consents or supplements hereto may be executed in any number of counterparts, and by
different parties hereto in separate counterparts, each of which when so delivered shall be deemed an original, but all of which
counterparts shall constitute but one and the same instrument.

 

11.16         No
Third Party Beneficiaries. No provisions of the Loan Documents are intended, nor will be interpreted, to provide or create any
third-party beneficiary rights or any other rights of any kind in any person other than Lender and Borrower unless specifically
provided otherwise herein, and, except as otherwise so provided, all provisions of the Loan Documents will be personal and solely
between the Lender and the Borrower.

 

11.17         Publicity.
(a)          Borrower consents to the publication and use by Lender and any of
its member businesses and affiliates of (i) Borrower's name (including a brief description of the relationship between Borrower
and Lender) and logo and a hyperlink to Borrower’s web site, separately or together, in written and oral presentations, advertising,
promotional and marketing materials, client lists, public relations materials or on its web site (together, the "Lender Publicity
Materials"); (ii) the names of officers of Borrower in the Lender Publicity Materials; and (iii) Borrower’s name, trademarks
or servicemarks in any news release concerning Lender.

 

Except as required by law or in connection with the
Borrower’s public filings with the SEC, neither Borrower nor any of its member businesses and affiliates shall, without Lender’s
consent, publicize or use (i) Lender's name (including a brief description of the relationship between Borrower and Lender), logo
or hyperlink to Lender’s web site, separately or together, in written and oral presentations, advertising, promotional and
marketing materials, client lists, public relations materials or on its web site (together, the "Borrower Publicity Materials");
(ii) the names of officers of Lender in the Borrower Publicity Materials; and (iii) Lender’s name, trademarks, servicemarks
in any news release concerning Borrower.

 

(SIGNATURES TO FOLLOW)

 

    	32

    	 

    

 

IN WITNESS WHEREOF, Borrower and Lender
have duly executed and delivered this Loan and Security Agreement as of the day and year first above written.

 

	 	BORROWER:
	 	 
	 	NEURALSTEM, INC.
	 	 	 
	 	Signature:	 
	 	 	 
	 	Print Name:	Richard Garr
	 	 	 
	 	Title:	Chief Executive Officer

 

Accepted in Palo Alto, California:

 

	 	LENDER:
	 	 
	 	HERCULES TECHNOLOGY III, L.P.,
	 	a Delaware limited partnership
	 	 	 
	 	By:	Hercules Technology SBIC
	 	 	Management, LLC, its General
	 	 	Partner
	 	 	 
	 	By:	Hercules Technology Growth
	 	 	Capital, Inc., its Manager
	 	 	 
	 	By:	 
	 	Name:	 
	 	Its:	 

 

    	33

    	 

    

 

Table of Addenda, Exhibits and Schedules

 

	Addendum 1:	SBA Provisions
	 	 
	Exhibit A:	Advance Request
	 	Attachment to Advance Request
	 	 
	Exhibit B:	Term Note
	 	 
	Exhibit C:	Name, Locations, and Other Information for Borrower
	 	 
	Exhibit D:	Borrower’s Patents, Trademarks, Copyrights and Licenses
	 	 
	Exhibit E:	Borrower’s Deposit Accounts and Investment Accounts
	 	 
	Exhibit F:	Compliance Certificate
	 	 
	Exhibit G:	Joinder Agreement
	 	 
	Exhibit H:	ACH Debit Authorization Agreement
	 	 
	Exhibit I:	Conversion Election Notice
	 	 
	Schedule 1	Subsidiaries
	Schedule 1A	Existing Permitted Indebtedness
	Schedule 1B	Permitted Investments
	Schedule 1C	Existing Permitted Liens
	Schedule 5.3	Consents, Etc.
	Schedule 5.5	Actions Before Governmental Authorities
	Schedule 5.8	Tax Matters
	Schedule 5.9	Intellectual Property Claims
	Schedule 5.10	Intellectual Property
	Schedule 5.11	Borrower Products
	Schedule 5.14	Capitalization

 

    	34

    	 

    

 

ADDENDUM 1 to LOAN AND SECURITY AGREEMENT

 

(a)          Borrower’s
Business.  For purposes of this Addendum 1, Borrower shall be deemed to include its “affiliates” as defined
in Title 13 Code of Federal Regulations Section 121.103.  Borrower represents and warrants to Lender as of the Closing Date
and covenants to Lender for a period of one year after the Closing Date with respect to subsections 2, 3, 4, 5, 6 and 7 below,
as follows:

 

		1.	Size Status.  Borrower does not have tangible net worth in excess of $18 million or average
net income after Federal income taxes (excluding any carry-over losses) for the preceding two completed fiscal years in excess
of $6 million;

 

		2.	No Relender.  Borrower’s primary business activity does not involve, directly or indirectly,
providing funds to others, purchasing debt obligations, factoring, or long-term leasing of equipment with no provision for maintenance
or repair;

 

		3.	No Passive Business.  Borrower is engaged in a regular and continuous business operation (excluding
the mere receipt of payments such as dividends, rents, lease payments, or royalties).  Borrower’s employees are carrying
on the majority of day to day operations.  Borrower will not pass through substantially all of the proceeds of the Loan to
another entity;

 

		4.	No Real Estate Business.  Borrower is not classified under Major Group 65 (Real Estate) or
Industry No. 1531 (Operative Builders) of the SIC Manual.  The proceeds of the Loan will not be used to acquire or refinance
real property unless Borrower (x) is acquiring an existing property and will use at least 51 percent of the usable square footage
for its business purposes; (y) is building or renovating a building and will use at least 67 percent of the usable square footage
for its business purposes; or (z) occupies the subject property and uses at least 67 percent of the usable square footage for its
business purposes.

 

		5.	No Project Finance.  Borrower’s assets are not intended to be reduced or consumed, generally
without replacement, as the life of its business progresses, and the nature of Borrower’s business does not require that
a stream of cash payments be made to the business's financing sources, on a basis associated with the continuing sale of assets
(e.g., real estate development projects and oil and gas wells).  The primary purpose of the Loan is not to fund production
of a single item or defined limited number of items, generally over a defined production period, where such production will constitute
the majority of the activities of Borrower (e.g., motion pictures and electric generating plants).

 

    	35

    	 

    

 

		6.	No Farm Land Purchases.  Borrower will not use the proceeds of the Loan to acquire farm land
which is or is intended to be used for agricultural or forestry purposes, such as the production of food, fiber, or wood, or is
so taxed or zoned.

 

		7.	No Foreign Investment.  The proceeds of the Loan will not be used substantially for a foreign
operation.  At the time of the Loan, Borrower will not have more than 49 percent of its employees or tangible assets located
outside the United States.  The representation in this subsection (7) is made only as of the date hereof and shall not continue
for one year as contemplated in the first sentence of this Section 1.

 

(b)          Small
Business Administration Documentation.  Lender acknowledges that Borrower completed, executed and delivered to Lender
SBA Forms 480, 652 and 1031 (Parts A and B) together with a business plan showing Borrower’s financial projections (including
balance sheets and income and cash flows statements) for the period described therein and a written statement (whether included
in the purchase agreement or pursuant to a separate statement) from Lender regarding its intended use of proceeds from the sale
of securities to Lender (the “Use of Proceeds Statement”).  Borrower represents and warrants to Lender that the
information regarding Borrower and its affiliates set forth in the SBA Form 480, Form 652 and Form 1031 and the
Use of Proceeds Statement delivered as of the Closing Date is accurate and complete.

 

(c)          Inspection. 
The following covenants contained in this Section (c) are intended to supplement and not to restrict the related provisions of
the Loan Documents.  Subject to the preceding sentence, Borrower will permit, for so long as Lender holds any debt or equity
securities of Borrower, Lender or its representative, at Lender’ expense, and examiners of the SBA to visit and inspect the
properties and assets of Borrower, to examine its books of account and records, and to discuss Borrower’s affairs, finances
and accounts with Borrower’s officers, senior management and accountants, all at such reasonable times as may be requested
by Lender or the SBA.

 

(d)          Annual
Assessment.  Promptly after the end of each calendar year (but in any event prior to February 28 of each year) and
at such other times as may be reasonably requested by Lender, Borrower will deliver to Lender a written assessment of the economic
impact of Lender’ investment in Borrower, specifying the full-time equivalent jobs created or retained in connection with
the investment, the impact of the investment on the businesses of Borrower in terms of expanded revenue and taxes, other economic
benefits resulting from the investment (such as technology development or commercialization, minority business development, or
expansion of exports) and such other information as may be required regarding Borrower in connection with the filing of Lender’s
SBA Form 468.   Lender will assist Borrower with preparing such assessment.  In addition to any other rights granted
hereunder, Borrower will grant Lender and the SBA access to Borrower’s books and records for the purpose of verifying the
use of such proceeds.  Borrower also will furnish or cause to be furnished to Lender such other information regarding the
business, affairs and condition of Borrower as Lender may from time to time reasonably request.

 

    	36

    	 

    

 

(e)          Use
of Proceeds.  Borrower will use the proceeds from the Loan only for purposes set forth in Section 7.14.  Borrower
will deliver to Lender from time to time promptly following Lender’s request, a written report, certified as correct by Borrower's
Chief Financial Officer, verifying the purposes and amounts for which proceeds from the Loan have been disbursed.  Borrower
will supply to Lender such additional information and documents as Lender reasonably requests with respect to its use of proceeds
and will permit Lender and the SBA to have access to any and all Borrower records and information and personnel as Lender deems
necessary to verify how such proceeds have been or are being used, and to assure that the proceeds have been used for the purposes
specified in Section 7.14.

 

(f)          Activities
and Proceeds.  Neither Borrower nor any of its affiliates (if any) will engage in any activities or use directly or indirectly
the proceeds from the Loan for any purpose for which a small business investment company is prohibited from providing funds by
the SBIC Act, including 13 C.F.R. §107.720.  Without obtaining the prior written approval of Lender, Borrower will
not change within 1 year of the date hereof, Borrower’s current business activity to a business activity which a licensee
under the SBIC Act is prohibited from providing funds by the SBIC Act.

 

(g)          Compliance
and Resolution.   Borrower agrees that a failure to comply with Borrower’s obligations under this Addendum,
or any other set of facts or circumstances where it has been asserted by any governmental regulatory agency (or Lender believes
that there is a substantial risk of such assertion) that Lender and its affiliates are not entitled to hold, or exercise any significant
right with respect to, any securities issued to Lender by Borrower, will constitute a breach of the obligations of Borrower under
the financing agreements between Borrower and Lender.  In the event of (i) a failure to comply with Borrower’s obligations
under this Addendum; or (ii) an assertion by any governmental regulatory agency (or Lender believes that there is a substantial
risk of such assertion) of a failure to comply with Borrower’s obligations under this Addendum, then (i) Lender and Borrower
will meet and resolve any such issue in good faith to the satisfaction of Borrower, Lender, and any governmental regulatory agency,
and (ii) upon request of Lender, Borrower will cooperate and assist with any assignment of the financing agreements from Hercules
Technology III, L.P. to Hercules Technology Growth Capital, Inc.

 

    	37

    	 

    

 

EXHIBIT
A

 

ADVANCE
REQUEST

 

	To:	Lender:	Date:	__________, 2013

 

HERCULES TECHNOLOGY III, L.P.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

Facsimile: 650-473-9194

Attn:

 

Neuralstem, Inc. (“Borrower”) hereby requests from
HERCULES TECHNOLOGY III, L.P. (“Lender”) an Advance in the amount of _____________________ Dollars ($________________)
on ______________, _____, 2013 (the “Advance Date”) pursuant to the Loan and Security Agreement between Borrower and
Lender (the “Agreement”). Capitalized words and other terms used but not otherwise defined herein are used with the
same meanings as defined in the Agreement.

 

Please:

 

(a)          Issue
a check payable to Borrower                ________

 

or

 

(b)          Wire
Funds to Borrower’s account               ________

 

	Bank:	 	 
	Address:	 	 
	 	 	 
	ABA Number:	 	 
	Account Number:	 	 
	Account Name:	 	 

 

Borrower represents that the conditions
precedent to the Advance set forth in the Agreement are satisfied and shall be satisfied upon the making of such Advance, including
but not limited to: (i) that no event that has had or could reasonably be expected to have a Material Adverse Effect has occurred
and is continuing; (ii) that the representations and warranties set forth in the Agreement and in the Warrant are and shall
be true and correct in all material respects on and as of the Advance Date with the same effect as though made on and as of such
date, except to the extent such representations and warranties expressly relate to an earlier date; (iii) that Borrower is
in compliance with all the terms and provisions set forth in each Loan Document on its part to be observed or performed; and (iv) that
as of the Advance Date, no fact or condition exists that would (or would, with the passage of time, the giving of notice, or both)
constitute an Event of Default under the Loan Documents. Borrower understands and acknowledges that Lender has the right to review
the financial information supporting this representation and, based upon such review in its sole discretion, Lender may decline
to fund the requested Advance.

 

    	38

    	 

    

 

Borrower hereby represents that Borrower’s
corporate status and locations have not changed since the date of the Agreement or, if the Attachment to this Advance Request is
completed, are as set forth in the Attachment to this Advance Request.

 

Borrower agrees to notify Lender promptly
before the funding of the Loan if any of the matters which have been represented above shall not be true and correct on the Borrowing
Date and if Lender has received no such notice before the Advance Date then the statements set forth above shall be deemed to have
been made and shall be deemed to be true and correct as of the Advance Date.

 

Executed as of March __, 2013.

 

	 	BORROWER: NEURALSTEM, INC.
	 	 	 
	 	SIGNATURE:	 

	 	TITLE:	 

	 	PRINT NAME:	 

 

    	39

    	 

    

 

ATTACHMENT
TO ADVANCE REQUEST

 

Dated: _______________________

 

Borrower hereby represents and warrants to Lender that Borrower’s
current name and organizational status is as follows:

 

	Name:	Neuralstem, Inc.
	 	 
	Type of organization:	Corporation
	 	 
	State of organization:	Delaware
	 	 
	Organization file number:	3357784

 

Borrower hereby represents and warrants to Lender that the street
addresses, cities, states and postal codes of its current locations are as follows:

 

LOCATIONS OF COMPANY
AND ITS SUBSIDIARIES

 

a.           The
Company and each of its subsidiaries maintain books or records at the following addresses:

 

	Complete street and mailing address, including county	 	
        Name of

        Company/Subsidiary

	 	 	 
	9700 Great Seneca Highway, Rockville, Maryland 20850	 	Neuralstem, Inc.,
	 	 	 
	9700 Great Seneca Highway, Rockville, Maryland 20850	 	Suzhou Neuralstem Biopharmaceutical Co., Ltd

 

b.           The
Company and its subsidiaries own, lease, or occupy real property located at the following addresses and maintain equipment, inventory,
or other property at such address:

 

	Complete street and mailing address, including county	 	
        Name of

        Company/Subsidiary
	 	Equipment/Inventory/other Collateral
	 	 	 	 	 
	9700 Great Seneca Highway, Rockville, Maryland 20850	 	Neuralstem, Inc.	 	Lab Equipment/Furniture
	 	 	 	 	 
	
        Suzhou Industrial Park Building A3, Xin Hu Rd#

        218.,
	 	Suzhou Neuralstem Biopharmaceutical Co., Ltd	 	Lab Equipment
	 	 	 	 	 
	1105 Flintkote Avenue, San Diego, CA  92128	 	Neuralstem, Inc.	 	Lab Equipment/Furniture
	 	 	 	 	 
	Charles River Labs, Malvern PA	 	Neuralstem, Inc.	 	Biological Materials
	 	 	 	 	 
	Genetics and IVF Institute, Gaithersburg, MD	 	Neuralstem, Inc.	 	Biological Materials
	 	 	 	 	 
	PM Machine / Duke Manufacturing, Willoughby, Ohio	 	Neuralstem, Inc.	 	Spinal Platforms (Inventory)

 

    	40

    	 

    

 

c.           The
following are the names and addresses of all warehousemen, bailees, or other third parties who have possession of any of the Company’s
inventory, equipment, or other property or that of its subsidiaries:

 

	
        Name and complete mailing address of third

        party
	 	
        Description of assets held with third party

        including estimated FMV
	 	
        Name of

        Company/Subsidiary

	 	 	 	 	 
	N/A	 	 	 	 

 

    	41

    	 

    

 

EXHIBIT
B

 

SECURED
TERM PROMISSORY NOTE

 

	$[  ],000,000	Advance Date:  ___ __, 20[  ]
	 	 
	 	Maturity Date:  _____ ___, 20[  ]

 

FOR VALUE RECEIVED, [                                             ],
a [                ] corporation, for itself and
each of its Subsidiaries (the “Borrower”) hereby promises to pay to the order of Hercules Technology III, L.P., a Delaware
limited partnership or the holder of this Note (the “Lender”) at 400 Hamilton Avenue, Suite 310, Palo Alto, CA 94301
or such other place of payment as the holder of this Secured Term Promissory Note (this “Promissory Note”) may specify
from time to time in writing, in lawful money of the United States of America, the principal amount of [ ] Million Dollars ($[
],000,000) or such other principal amount as Lender has advanced to Borrower, together with interest at a floating rate equal to
the greater of either (i) 11.0% plus the prime rate as reported in The Wall Street Journal, and if not reported, then the prime
rate next reported in the Wall Street Journal, minus 3.25%, or (ii) 11.0%., with interest computed daily based on the actual number
of days in each month.

 

This Promissory Note is the Note referred
to in, and is executed and delivered in connection with, that certain Loan and Security Agreement dated March 22, 2013, by and
between Borrower and Lender (as the same may from time to time be amended, modified or supplemented in accordance with its terms,
the “Loan Agreement”), and is entitled to the benefit and security of the Loan Agreement and the other Loan Documents
(as defined in the Loan Agreement), to which reference is made for a statement of all of the terms and conditions thereof. All
payments shall be made in accordance with the Loan Agreement, including
the right of Borrower to pay a portion of the amounts due and owing under this Promissory Note in shares of Common Stock in accordance
with, and subject to the limitations set forth in, Section 2.1(f) of the Loan Agreement (including the requirement that any shares
of Common Stock issuable by Borrower upon conversion of this Note are subject to an effective resale registration statement or
are eligible for resale to the public pursuant to Rule 144 without any limitation). All terms defined in the Loan Agreement
shall have the same definitions when used herein, unless otherwise defined herein. An Event of Default under the Loan Agreement
shall constitute a default under this Promissory Note.

 

Borrower waives presentment and demand for
payment, notice of dishonor, protest and notice of protest under the UCC or any applicable law. Borrower agrees to make all payments
under this Promissory Note without setoff, recoupment or deduction and regardless of any counterclaim or defense. This Promissory
Note has been negotiated and delivered to Lender and is payable in the State of California. This Promissory Note shall be governed
by and construed and enforced in accordance with, the laws of the State of California, excluding any conflicts of law rules or
principles that would cause the application of the laws of any other jurisdiction.

 

	BORROWER FOR ITSELF AND	 	 
	ON BEHALF OF ITS SUBSIDIARIES:	[                                         ]
	 	 	 
	 	By:	 
	 	Title:	 

 

    	 

    	 

    

 

EXHIBIT
C

 

NAME, LOCATIONS,
AND OTHER INFORMATION FOR BORROWER

 

1.  Borrower represents and warrants
to Lender that Borrower’s current name and organizational status as of the Closing Date is as follows:

 

	Name:	Neuralstem, Inc.
	 	 
	Type of organization:	Corporation
	 	 
	State of organization:	Delaware
	 	 
	Organization file number:	DE File Number 3357784

 

2.  Borrower represents and warrants
to Lender that for five (5) years prior to the Closing Date, Borrower did not do business under any other name or organization
or form except the following:

 

Name:  Neuralstem, Inc.

Used during dates of:  Since inception

Type of Organization:  C Corporation

State of organization:  Delaware

Organization file Number:  DE File Number
3357784

Borrower’s fiscal year ends on 12/31

Borrower’s federal employer tax identification
number is: 52-2007292

 

3.  Borrower represents
and warrants to Lender that its chief executive office is located at:

 

9700 Great Seneca Highway,
Rockville, Maryland.

 

    	 

    	 

    

 

EXHIBIT
D

 

BORROWER’S
PATENTS, TRADEMARKS, COPYRIGHTS AND LICENSES

 

The table
below lists all US Patents Owned by Neuralstem, Inc.

 

	
        Patent

        #
	 	Issued	 	Title
	5,753,506	 	5/19/1998	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	6,040,180	 	3/21/2000	 	IN VITRO GENERATION OF DIFFERENTIATED NEURONS FROM CULTURES OF MAMMALIAN MULTIPOTENTIAL CNS STEM CELLS
	6,284,539	 	9/4/2001	 	METHOD FOR GENERATING DOPAMINERGIC CELLS DERIVED FROM NEURAL PRECURSORS
	7,544,511	 	6/9/2009	 	STABLE NEURAL STEM CELL LINES
	7,691,629	 	4/6/2010	 	TRANSPLANTATION OF HUMAN NEURAL CELLS FOR TREATMENT OF NEUROLOGICAL DISORDERS
	8,236,299	 	8/7/2012	 	METHODS OF TREATING SPINAL CORD INJURY
	 	 	 	 	 
	8,293,488	 	10/23/2012	 	METHOD FOR DISCOVERING NEUROGENIC AGENTS
	7,858,628	 	12/28/2010	 	USE OF FUSED NICOTINAMIDES TO PROMOTE NEUROGENESIS
	7,560,553	 	7/14/2009	 	USE OF FUSED NICOTINAMIDES TO PROMOTE NEUROGENESIS
	 	 	 	 	 
	8,058,434	 	11/15/2011	 	COMPOSITIONS TO EFFECT NEURONAL GROWTH
	 	 	 	 	 
	8,030,492	 	10/4/2011	 	COMPOSITIONS TO EFFECT NEURONAL GROWTH
	 	 	 	 	 
	8,362,262	 	1/29/2013	 	COMPOSTITIONS AND METHODS OF USE

 

The table
below lists all US Patents PENDING FOR Neuralstem, Inc.

 

	
        Application

        Number
	 	
        Filing

        Date
	 	Title
	12/404,841	 	3/16/2009	 	METHODS OF TREATING SPINAL CORD INJURY
	12/424,238	 	4/15/2009	 	STABLE NEURAL STEM CELL LINES
	13/192,972	 	7/28/2011	 	METHODS FOR TREATING AND/OR REVERSING NEURODEGENERATIVE DISEASES AND/OR DISORDERS
	13/392,489	 	2/24/2012	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE

 

    	 

    	 

    

 

The table
below lists ALL US Patents Exclusively Licensed by Neuralstem, Inc. From Cleveland Clinic

 

	
        Patent

        #
	 	Issued	 	Title
	8,092,495	 	1/10/2012	 	TARGETED SPINAL CORD THERAPEUTICS DELIVERY
	7,833,217	 	11/16/2010	 	FLOATING SPINAL CANNULA AND METHOD OF USE

 

The table
below lists all Foreign Patents Owned by Neuralstem, Inc.

 

	Patent #	 	Issued	 	Country	 	Title
	0915968	 	7/25/2007	 	EUROPEAN PATENT CO	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	755849	 	4/3/2003	 	AUSTRALIA	 	STABLE NEURAL STEM CELL LINES
	2343571	 	1/3/2012	 	CANADA	 	STABLE NEURAL STEM CELL LINES
	4709382	 	3/25/2011	 	JAPAN	 	STABLE NEURAL STEM CELL LINES
	0915968	 	7/25/2007	 	SWITZERLAND	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	69737949.3	 	7/25/2007	 	GERMANY	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	0915968	 	7/25/2007	 	SPAIN	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	0915968	 	7/25/2007	 	FRANCE	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	0915968	 	7/25/2007	 	IRELAND	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	0915968	 	7/25/2007	 	UNITED KINGDOM	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	0915968	 	7/25/2007	 	SWEDEN	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	183092	 	3/1/2012	 	ISRAEL	 	METHODS OF TREATING SPINAL CORD INJURY
	2434636	 	11/27/2011	 	RUSSIA, FEDERATION OF	 	METHODS OF TREATING SPINAL CORD INJURY
	132324	 	11/30/2009	 	SINGAPORE	 	METHODS OF TREATING SPINAL CORD INJURY
	10524	 	10/3/2012	 	VIETNAM	 	METHODS OF TREATING SPINAL CORD INJURY
	204356	 	12/28/2011	 	ISRAEL	 	METHODS OF TREATING SPINAL CORD INJURY

 

    	 

    	 

    

 

The table
below lists all FOREIGN Patents PENDING FOR Neuralstem, Inc.

 

	
        Application

        #
	 	
        Filing

        Date
	 	Country	 	Title
	2010289802	 	8/24/2010	 	AUSTRALIA	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	037903564	 	12/5/2003	 	BELGIAN	 	METHOD FOR DISCOVERING NEUROGENIC AGENTS
	1120120041614	 	8/24/2010	 	BRAZIL	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	2257068	 	5/7/1997	 	CANADA	 	ISOLATION PROPAGATION AND DIRECTED DIFFERENTIATION OF STEM CELLS FROM EMBRYONIC AND ADULT CENTRAL NERVOUS SYSTEM OF MAMMALS
	2772080	 	8/24/2010	 	CANADA	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	4932012	 	8/24/2010	 	CHILE	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	200580039450	 	11/17/2005	 	CHINA	 	METHODS OF TREATING SPINAL CORD INJURY
	2010800465155	 	8/24/2010	 	CHINA	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	99948396.9	 	9/20/1999	 	EUROPEAN PATENT CO	 	STABLE NEURAL STEM CELL LINES
	037903564	 	12/5/2003	 	EUROPEAN PATENT CO	 	METHOD FOR DISCOVERING NEUROGENIC AGENTS
	05851748.3	 	11/17/2005	 	EUROPEAN PATENT CO	 	METHODS OF TREATING SPINAL CORD INJURY
	108142605	 	8/24/2010	 	EUROPEAN PATENT CO	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	08106303.1	 	6/5/2008	 	HONG KONG	 	METHODS OF TREATING SPINAL CORD INJURY
	2613/CHENP/2007	 	11/17/2005	 	INDIA	 	METHODS OF TREATING SPINAL CORD INJURY
	2370DELNP2012	 	8/24/2010	 	INDIA	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	W00201201102	 	8/24/2010	 	Indonesia	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	pending	 	8/24/2010	 	ISRAEL	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	2007-543219	 	11/17/2005	 	JAPAN	 	METHODS OF TREATING SPINAL CORD INJURY
	2012526928	 	8/24/2010	 	JAPAN	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE

 

    	 

    	 

    

 

	2010-254952	 	11/15/2010	 	JAPAN	 	STABLE NEURAL STEM CELL LINES
	2012-20641	 	2/2/2012	 	JAPAN	 	METHODS OF TREATING SPINAL CORD INJURY
	1020127007653	 	8/24/2010	 	KOREA	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	MXA2012002335	 	8/24/2010	 	MEXICO	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	598891	 	8/24/2010	 	NEW ZEALAND	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	20073078	 	11/17/2005	 	NORWAY	 	METHODS OF TREATING SPINAL CORD INJURY
	PCT/US2010/046537	 	8/24/2010	 	PCT INTERNATIONAL	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	PCT/US2011/045732	 	7/28/2011	 	PCT INTERNATIONAL	 	METHODS FOR TREATING AND/OR REVERSING NEURODEGENERATIVE DISEASES AND/OR DISORDERS
	1-2007-501016	 	11/17/2005	 	PHILIPPINES	 	METHODS OF TREATING SPINAL CORD INJURY
	12010502167	 	9/23/2010	 	PHILIPPINES	 	METHODS OF TREATING SPINAL CORD INJURY
	12012500395	 	8/24/2010	 	PHILLIPINES	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	2012111227	 	8/24/2010	 	RUSSIA, FEDERATION OF	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	2011131830	 	7/28/2011	 	RUSSIA, FEDERATION OF	 	METHODS OF TREATING SPINAL CORD INJURY
	2012012878	 	8/24/2010	 	SINGAPORE	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE
	10-2007-7012097	 	11/17/2005	 	SOUTH KOREA	 	METHODS OF TREATING SPINAL CORD INJURY
	1201000761	 	8/24/2010	 	THAILAND	 	SYNTHESIS OF A NEUROSTIMULATIVE PIPERAZINE

 

The table
below lists the FOREIGN Patents PENDING Exclusively Licensed by Neuralstem, Inc. From Cleveland Clinic

 

	
        Application

        #
	 	
        Filing

        Date
	 	Country	 	Title
	PCT/US09/39451	 	4/3/2009	 	EUROPEAN PATENT CO	 	Spinal Platform and Method for Delivering a Therapeutic Agent to a Spinal Cord Target
	PCT/US09/49427	 	7/1/2009	 	EUROPEAN PATENT CO	 	Floating Cannula and Method Of Use

 

    	 

    	 

    

 

THE TABLE BELOW LISTS ALL US PATENTS PENDING EXCLUSIVELY
LICENSED BY NEURALSTEM, INC. FROM CLEVELAND CLINIC

 

	
        Application

        Number
	 	Filing Date	 	Title
	12/913,527	 	10/27/2010	 	FLOATING CANNULA AND METHODS OF USE

 

Neuralstem
DOES NOT Hold ANY TrademarkS at the PRESENT TIME

 

Neuralstem
Does not Hold any Copyrights at the present time

 

Neuralstem
Holds the Exclusive Worldwide License Rights to the Spinal Platform and Floating Cannula technologies developeD TO DELIVER OUR
HUMAN NEURAL STEM CELLS to a Spinal Cord Target. This TECHNOLOGY HAS BEEN SUBLICENSED TO TWO COMPANIES TO DATE: Q Therapeutics
and CEDARS SINAI.

 

    	 

    	 

    

 

EXHIBIT
E

 

BORROWER’S
DEPOSIT ACCOUNTS AND INVESTMENT ACCOUNTS

 

 

    	 

    	 

    

 

EXHIBIT
F

 

COMPLIANCE
CERTIFICATE

 

HERCULES TECHNOLOGY III, L.P.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

 

Reference is made to that certain Loan and
Security Agreement dated March 22, 2013, and all ancillary documents entered into in connection with such Loan and Security Agreement
all as may be amended from time to time, (hereinafter referred to collectively as the “Loan Agreement”) between HERCULES
TECHNOLOGY III, L.P. (“Hercules”) as Lender and Neuralstem, Inc. (the “Company”) as Borrower. All capitalized
terms not defined herein shall have the same meaning as defined in the Loan Agreement.

 

The undersigned is an Officer of the Company,
knowledgeable of all Company financial matters, and is authorized to provide certification of information regarding the Company;
hereby certifies that in accordance with the terms and conditions of the Loan Agreement, the Company is in compliance for the period
ending ___________ of all covenants, conditions and terms and hereby reaffirms that all representations and warranties contained
therein are true and correct on and as of the date of this Compliance Certificate with the same effect as though made on and as
of such date, except to the extent such representations and warranties expressly relate to an earlier date, after giving effect
in all cases to any standard(s) of materiality contained in the Loan Agreement as to such representations and warranties. Attached
are the required documents supporting the above certification. The undersigned further certifies that these are prepared in accordance
with GAAP (except for the absence of footnotes with respect to unaudited financial statement and subject to normal year end adjustments)
and are consistent from one period to the next except as explained below.

 

	REPORTING REQUIREMENT	REQUIRED	
        CHECK IF

        ATTACHED

	 	 	 
	Interim Financial Statements 	Monthly within 30 days	 
	 	 	 
	Interim Financial Statements 	Quarterly within 50 days	 
	 	 	 
	Audited Financial Statements 	FYE within 150 days	 

 

	 	Very Truly Yours,
	 	 
	 	NEURALSTEM, INC.
	 	 	 
	 	By:	 
	 	 	 
	 	Name:	 
	 	 	 
	 	Its:	 

 

    	 

    	 

    

 

EXHIBIT
G

 

FORM OF
JOINDER AGREEMENT

 

This Joinder Agreement (the “Joinder
Agreement”) is made and dated as of [              ], 20[  ], and is entered into by and between__________________., a ___________ corporation
(“Subsidiary”), and HERCULES TECHNOLOGY III, L.P. as a Lender.

 

RECITALS

 

A. Subsidiary’s Affiliate, [                              ]
(“Company”) [has entered/desires to enter] into that certain Loan and Security Agreement dated March 22, 2013, with
Lender, as such agreement may be amended (the “Loan Agreement”), together with the other agreements executed and delivered
in connection therewith;

 

B. Subsidiary acknowledges and agrees that
it will benefit both directly and indirectly from Company’s execution of the Loan Agreement and the other agreements executed
and delivered in connection therewith;

 

AGREEMENT

 

NOW THEREFORE, Subsidiary and Lender agree
as follows:

 

		1.	The recitals set forth above are incorporated into and made part of this Joinder Agreement. Capitalized
terms not defined herein shall have the meaning provided in the Loan Agreement.

 

		2.	By signing this Joinder Agreement, Subsidiary shall be bound by the terms and conditions of the
Loan Agreement the same as if it were the Borrower (as defined in the Loan Agreement) under the Loan Agreement, mutatis mutandis,
provided however, that Lender shall have no duties, responsibilities or obligations to Subsidiary arising under or related to the
Loan Agreement or the other agreements executed and delivered in connection therewith. Rather, to the extent that Lender has any
duties, responsibilities or obligations arising under or related to the Loan Agreement or the other agreements executed and delivered
in connection therewith, those duties, responsibilities or obligations shall flow only to Company and not to Subsidiary or any
other person or entity. By way of example (and not an exclusive list): (a) Lender’s providing notice to Company in accordance
with the Loan Agreement or as otherwise agreed between Company and Lender shall be deemed provided to Subsidiary; (b) a Lender’s
providing an Advance to Company shall be deemed an Advance to Subsidiary; and (c) Subsidiary shall have no right to request an
Advance or make any other demand on Lender.

 

[REMAINDER OF PAGE INTENTIONALLY
LEFT BLANK]

 

    	 

    	 

    

 

[SIGNATURE PAGE TO JOINDER
AGREEMENT]

 

SUBSIDIARY:

 

_________________________________.

 

	 	By:	 	 
	 	Name:	 	 
	 	Title:	 	 
	 	 	 	 
	 	Address:	 
	 	 	 
	 	Telephone: ___________	 
	 	Facsimile: ____________	 

 

LENDER:

 

HERCULES TECHNOLOGY III, L.P.,

a Delaware limited partnership

 

	 	By:	Hercules Technology SBIC Management, LLC,
	 	 	 
	 	 	its General Partner
	 	 	 
	 	By	Hercules Technology Growth Capital, Inc.,
	 	 	 
	 	 	its Manager
	 	 	 	 
	 	 	By:	 	 
	 	 	Name:	 	 
	 	 	Its:	 	 

 

Address:

	 	400 Hamilton Ave., Suite 310
	 	Palo Alto, CA 94301
	 	Facsimile:  650-473-9194
	 	Telephone:  650-289-3060

 

    	 

    	 

    

 

EXHIBIT
H

 

ACH DEBIT
AUTHORIZATION AGREEMENT

 

HERCULES TECHNOLOGY III, L.P.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

 

Re: Loan and Security Agreement
dated March 22, 2013 between Neuralstem, Inc. (“Borrower”) and HERCULES TECHNOLOGY III, L.P. (“Company”)
(the “Agreement”)

 

In connection with the above referenced
Agreement, the Borrower hereby authorizes the Company to initiate debit entries for the periodic payments due under the Agreement
to the Borrower’s account indicated below. The Borrower authorizes the depository institution named below to debit to such
account.

 

	Depository Name	Branch
	 	 
	City	State and Zip Code
	 	 
	Transit/ABA Number	Account Number

 

This authority will remain in full force
and effect so long as any amounts are due under the Agreement.

 

	 	 
	(Borrower)(Please Print)	 
	 	 	 
	By:	 	 
	 	 	 
	Date:	 	 

 

    	 

    	 

    

 

EXHIBIT
I

 

CONVERSION
ELECTION NOTICE

 

[INSERT DATE]

 

Hercules Technology III, L.P.

400 Hamilton Avenue, Suite 310

Palo Alto, CA 94301

 

Reference
is made to that certain Loan and Security Agreement dated March __, 2013 and all ancillary documents entered into in connection
with such Loan and Security Agreement all as may be amended from time to time, (hereinafter referred to collectively as the “Loan
Agreement”) between Hercules Technology III, L.P., as
Lender, and Neuralstem, Inc. (the “Company”) as Borrower. All capitalized terms not defined herein shall have the same
meaning as defined in the Loan Agreement.

 

Borrower
hereby irrevocably elects to make the Principal Installment Payment in the amount of $_________ due on [________] (the “Delivery
Date”) in shares of Common Stock in accordance with Section 2.1(f) of the Loan Agreement.1
The number of shares of Common Stock to be delivered to Lender, on or prior to the Delivery Date, is [_____________], which amount
was determined in accordance with Section 2.1(f) of the Loan Agreement. The stock certificates shall be delivered free and clear
of any restrictive legends.

 

Borrower hereby represents,
warrants and certifies to Lender that, as of the date hereof, all of the Conversion Conditions have been satisfied. Borrower acknowledges
and agrees that its right to pay the Principal Installment Payment in Common Stock in accordance with this Conversion Election
Notice is subject to the satisfaction of all of the Conversion Conditions on the Delivery Date and, to the extent any of the Conversion
Conditions are not satisfied on the Delivery Date, Borrower shall pay the Principal Installment Payment in cash.

 

	 	Sincerely,	 
	 	 	 
	 	NEURALSTEM, INC.	 
	 	 	 	 
	 	By:	 	 
	 	 	 	 
	 	Name:	 	 
	 	 	 	 
	 	Its:	 	 

 

 

 

1 Note: In accordance
with Section 2.1(f) of the Loan Agreement, the Delivery Date must be at least 10 days following the date of delivery of this Conversion
Election Notice.

 

    	 

    	 

    

 

Schedule 1

 

SUBSIDIARIES

 

		1.	Suzhou Neuralstem Biopharmaceutical Co., Ltd

 

    	 

    	 

    

 

Schedule 1a

 

BORROWER’S INDEBTEDNESS

 

 

 

    	 

    	 

    

 

Schedule 1b

 

BORROWER’S INVESTMENTS

 

    	 

    	 

    

 

Schedule 1c

 

BORROWER’S LIENS

 

    	 

    	 

    

 

Schedule 5.3

 

CONSENTS

 

 

    	 

    	 

    

 

Schedule 5.5

 

ACTIONS BEFORE GOVERNMENTAL AUTHORITIES

 

 

    	 

    	 

    

 

Schedule 5.8

 

TAX MATTERS

 

 

    	 

    	 

    

 

Schedule 5.9

 

INTELLECTUAL PROPERTY CLAIMS

 

    	 

    	 

    

 

Schedule 5.10

 

INTELLECTUAL PROPERTY

 

    	 

    	 

    

 

Schedule 5.11

 

BORROWER’S PRODUCTS AND INTELLECTUAL
PROPERTY

 

    	 

    	 

    

 

Schedule 5.14

 

BORROWER’S CAPITALIZATION AND SUBSIDIARIES

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00215-of-00352.parquet"}]]